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Summary 
Significance of colonoscopy in screening for colorectal cancer 
Colonoscopy is the final common pathway of all screening for colorectal 
cancer (CRC) and is used for biopsy and polyp removal. For a screening-test 
in the (healthy) general population colonoscopy is invasive and prone to se-
rious complications. Screening-yield and rates of complications are strongly 
dependent on the individual operator and on quality assurance. As a result, 
training and continued education of endoscopists as well as monitoring of 
both detection and complication rates are key to high screening-quality. 
 
Effectiveness of screening for CRC 
No data is currently available on the impact of CRC-screening on all-cause 
mortality. Four randomized controlled trials on screening for faecal occult 
blood as a first-line test (gFOBT) showed a relative risk reduction of 15% for 
disease-specific CRC-mortality. A large randomized controlled trial on once 
only flexible sigmoidoscopy as a first-line test showed a relative risk reduc-
tion of 31% for disease-specific CRC-mortality and a reduction of CRC in-
cidence of 23%. Results from three more randomized trials on flexible sig-
moidoscopy are expected in the coming years. Two randomized studies on 
screening with colonoscopy as a first-line test will yield results starting ten 
years from now. There is only limited evidence on test characteristics (sensi-
tivity, specificity, complication rates) in real life screening-settings. 
 
International screening-activities 
In many countries the evaluation of evidence, the planning and at times the 
coordination of CRC-screening are done by a national institution. A few 
countries – England, Scotland, Finland and Australia – run organized popu-
lation-based programs. However, most screening is not population-based but 
opportunistic with low participation rates. Some countries – Japan, Italy and 
Germany – have programs that have been under way for many years. In the 
European Union about 70% of the population has access to some mode of 
CRC-screening. The most common first-line screening-test is gFOBT, to a 
degree also iFOBT. In some countries endoscopic-screening – colonoscopy, 
flexible sigmoidoscopy – is used as an alternative or in combination with 
FOBT. Also due to insurers’ remuneration decisions in the US, colonoscopy 
is the most common first-line screening-test there. 
 
Choice of first-line test 
When considering first-line screening-tests on which to base an organized 
program, the test’s impact on participation is more important than its test-
sensitivity. Program-sensitivity largely depends on participation rates. Re-
cent developments in first-line screening include quantitative iFOBTs. CT-
colonoscopy, capsule endoscopy and new molecular tests are not yet viable 
alternatives for use in population-based mass-screening. 
 
 
Colonoscopy … 
… final common 
pathway in all CRC-
screening 
… invasive, serious 
complications 
… operator-dependent 
 
 
limited evidence base 
for CRC-screening … 
… RCTs from gFOBT 
and recently flexible 
sigmoidoscopy 
… more sigmoidoscopy 
results expected soon 
no RCT evidence for 
colonoscopy 
most screening-activity 
not population-based … 
… but opportunistic 
with low participation 
rates 
first-line screening test’s 
impact on program 
participation more 
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sensitivity 
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Improving screening-effectiveness 
An upper age-limit for CRC-screening is recommended. An integrated 
screening-program combines screening with screening-relevant considera-
tions in diagnosis, treatment and surveillance. Along with standardized do-
cumentation and regular evaluation an integrated program-design provides 
the quality necessary to consider screening average risk-populations. Giving 
thorough attention to the design of the surveillance regime is important, be-
cause its thresholds determine the numbers of surveillance-colonoscopies re-
sulting from CRC-screening. Incremental implementation of a national 
population-based screening-program, with pilot testing and incremental 
roll-out, should be considered. 
 
Securing comprehensive program-financing 
Population-based screening-programs require significant initial investment 
in overhead and sustainable financing of ongoing documentation, quality as-
surance and evaluation. Also, ongoing financing of both program- and pro-
vider-independent information dissemination to potential screening-
participants and funds for regular program evaluation through an external 
institution needs to be secured. 
integrated screening – 
program considering 
diagnosis – treatment – 
surveillance 
incremental 
implementation of 
national program 
recommended 
 
comprehensive and 
sustainable program 
funding needs to be 
secured from the outset 
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Zusammenfassung 
Bedeutung der Koloskopie im Dickdarmkrebs-Screening 
Koloskopie ist – unabhängig von der Wahl des first-line Tests – Bestandteil 
jedes Screenings. Koloskopie wird jedenfalls als second-line Test und gege-
benenfalls zur Biopsie bzw. Entfernung entdeckter Polypen eingesetzt. Ko-
loskopie ist für eine Screening-Maßnahme, die sich an die gesunde Normal-
bevölkerung richtet, invasiv und komplikationsintensiv. Die Entdeckungs-
raten von Polypen und die Komplikationsraten sind stark von der/dem indi-
viduellen UntersucherIn und von umfassender Qualitätssicherung abhängig. 
Die Aus- und Weiterbildung der Endoskopierenden und das Monitoring der 
Ergebnisraten sind zentral für die Qualität von Dickdarmkrebs-Screening. 
 
Effektivität von Dickdarmkrebs-Screening 
Zum Einfluss von Darmkrebs-Screening auf die Gesamtsterblichkeit liegen 
keine Daten vor. Vier randomisierte Studien belegen für Screening mit ei-
nem Test auf Blut im Stuhl (gFOBT) eine Senkung der Darmkrebs-
spezifischen Sterblichkeit um 15%. Eine große randomisierte Studien belegt 
für einmaliges Screening mit flexibler Sigmoidoskopie eine Senkung der 
Darmkrebs-spezifischen Sterblichkeit um 31%. Die Inzidenz von CRC ging 
um 23% zurück. Ergebnisse dreier weiterer randomisierter Studien zu fle-
xibler Sigmoidoskopie werden im Verlauf der nächsten Jahre erwartet. Zwei 
randomisierte Studien über Screening mit Koloskopie werden erst in zehn 
Jahren Ergebnisse liefern. Über Charakteristika wie Sensitivität, Spezifität 
und Komplikationsraten der Tests im Kontext von Screening-Bedingungen 
in der Praxis gibt es wenig Evidenz. 
 
Screening-Aktivitäten international 
In vielen Ländern erfolgt die Bewertung der Evidenz, die Planung und teil-
weise die Koordinierung von Screening durch eine nationale Institution. 
Nur wenige Länder – wie England, Schottland, Finnland und Australien – 
verfügen über nationale populationsbezogene Programme. Meist erfolgt 
Screening aber nicht populationsbezogen im Rahmen eines qualitätsgesi-
cherten Programms, sondern opportunistisch und mit niedriger Teilnahme-
rate. In einigen Ländern – wie etwa in Japan, Italien und Deutschland – be-
stehen Programme bereits seit vielen Jahren. In der Europäischen Union 
haben etwa 70% der Bevölkerung Zugang zu der einen oder anderen Form 
von Dickdarmkrebs-Screening. Als first-line Screening-Test wird am häu-
figsten gFOBT, gefolgt von iFOBT, eingesetzt. Bisweilen besteht eine 
Wahlmöglichkeit zu Koloskopie oder flexibler Sigmoidoskopie. Nicht zu-
letzt aufgrund von Erstattungsentscheidungen von Krankenversicherungen 
in den USA ist dort Koloskopie der häufigste first-line Test. 
 
Koloskopie … 
… ist Hauptbestandteil 
jedes Screening-Pfads 
 ...ist invasive Screening-
Massnahme mit 
ha¨ufigen 
Komplikationen 
wenig Evidenz zur 
Effektivita¨t von 
Dickdarmkrebs-
Screening vorhanden 
… 4 RCTs zu gFOBT 
… 1 RCT zu 
Sigmoidskopie (weitere 
kommen) 
… keine RCT zu 
Koloskopie 
Screening erfolgt meist 
nicht 
populationsbezogen im 
Rahmen 
qualita¨tsgesicherter 
Programme … 
… sondern 
opportunistisch und mit 
niedrigen 
Teilnahmeraten 
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Auswahl eines first-line Tests 
Für die Auswahl eines first-line Screening-Tests ist seine Auswirkung auf 
die TeilnehmerInnenrate des Screening-Programms wichtiger als die Test-
Sensitivität. Die Sensitivität des Programms hängt maßgeblich von der 
TeilnehmerInnenrate ab. Als neue first-line Screening-Tests bieten sich 
quantitative iFOBTs an. CT-Koloskopie, Kapselendoskopie und neu entwi-
ckelte molekulare Test werden in absehbarer Zeit (noch) keine Alternativen 
für einen breiten Screening-Einsatz sein. 
 
Ansätze zur Steigerung der Effektivität 
Das Festlegen einer oberen Altersgrenze für die Teilnahme am Dickdarm-
krebs-Screening wird empfohlen. Ein mehrstufiges Programm, das die ver-
schiedenen AkteurInnen des Screenings und die nachgelagerten diagnosti-
schen, behandlerischen und Surveillance-Prozesse vernetzt, ermöglicht Qua-
litätssicherung, Dokumentation der Ergebnisse und deren Evaluation. Be-
sondere Bedeutung kommt der Gestaltung der dem Screening nachgelager-
ten Surveillance zu. Die dort formulierten Schwellenwerte legen die Anzahl 
der durch Screening induzierten Surveillance-Koloskopien fest. Bei der Ein-
führung eines populationsbezogenen Programms ist ein schrittweises Vor-
gehen, etwa über Pilottestungen und anschließendes schrittweises Ausrol-
len, überlegenswert. 
 
Komponenten der Programmfinanzierung 
Für den nicht unbeträchtlichen Overhead eines qualitätsgesicherten popula-
tionsbezogenen Programms zum Dickdarmkrebs-Screening ist eine nachhal-
tige Finanzierung Voraussetzung. Gleiches gilt für die Finanzierung der ex-
tern programmunabhängigen Bereitstellung von Informationen für poten-
zielle TeilnehmerInnen am Screening und für die Finanzierung der regel-
mäßigen Evaluation des Programms durch eine externe unabhängige Insti-
tution. 
 
 
 
Auswahl des Screening-
Tests: 
… Auswirkung auf 
Programmsensivita¨t 
u¨ber Teilnahmerate 
wichtiger  
… als Einzelsensitivita¨t 
des Tests 
 
Screening-Programm 
soll Vernetzung mit 
Diagnose, Behandlung 
und Surveillance sicher 
stellen 
… schrittweise 
Einfu¨hrung empfohlen 
 
ausreichende und 
nachhaltige 
Finanzierung fu¨r Erfolg 
des Screening-
Programms notwendig 
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1 Introduction 
1.1 Rationale for Colorectal Cancer-
Screening 
Colorectal cancer (CRC) or colorectal adenocarcinoma is a malignant tumor 
arising within the walls of the large intestine, including the segments in the 
cecum, ascending colon, transverse colon, descending colon, sigmoid and 
rectum. CRC does not include tumors in the tissues of the anus or the small 
intestine.1 CRC is common in industrialized countries. In terms of age-
standardized incidence rates, there exists little difference from one Euro-
pean country to another, nor is there a clear geographic pattern.2 Among 
both men and women CRC was the third most common non-skin cancer and 
also the third-highest cause of cancer death in the US in 2009.3 
CRC has a recognizable, protracted pre-malignant stage (adenoma) that is 
relatively easy to treat. If an adenoma has progressed to carcinoma, it is an 
average of nearly 7 years before the disease becomes symptomatic.4 If the 
disease is detected early, a person’s chances of survival are considerably 
higher than if it is detected at a later stage. That is why screening for CRC 
has been introduced in various modes of organization in a number of coun-
tries. 
1.2 Background and structure of this report 
The Swiss cancer league5 requested a review of the secondary literature 
(health technology assessments, systematic reviews, meta-analyses) on CRC-
screening to inform about policy options in this realm. The study questions 
guiding this report are: 
1. What screening-tests are available for CRC, what are the respective 
test characteristics and what are the respective test’s wider implica-
tion for a CRC-screening program? 
2. What questions and central aspects are to be considered in the con-
text of designing an organized population-based screening-program 
for CRC? 
After the ensuing methods section on the literature search, the quality of the 
three major health technology assessments – which are the main sources of 
information this report focuses on – is appraised. This is done according to 
the PRISMA-statement on preferred reporting items for systematic reviews 
and meta-analyses.6 Chapter 4 (results I) addresses the first study question 
and condenses the results of the literature review on important facts about 
                                                             
1 USPSTF Whitlock (2008a) p. 2 
2 Health Council of the Netherlands (2009) p. 32 
3 AHRQ Holden (2010) p. 25 
4 Health Council of the Netherlands (2009) p. 77 
5 www.krebsliga.ch/de/100_jahre_krebsliga/english.cfm 
6 The PRISMA statement: Moher (2009) 
Colorectal cancer (CRC) 
third most common 
non-skin cancer 
protracted pre-
malignant stage, early 
detection raises chance 
of survival 
Review of secondary 
literature on CRC-
Screening for Swiss 
cancer league … 
…  on choice of 
screening-test and 
general issues of 
program design 
report  focuses on three 
recent HTAs 
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CRC-screening. Chapter 5 (results II) addresses the second study question. 
Part of the focus here lies on distilling important questions on CRC-
screening and population-based screening-program design from the litera-
ture. The final chapter 6 concludes with a brief take-home message from the 
literature review for designing quality assured population-based CRC-
screening. 
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2 Methods 
2.1 Initial literature search and inclusion 
Dec. 2009 
The search was conducted on Dec. 22nd 2009 with the following PICO7 –
question: 
 
“Can (newer) faecal occult blood tests/ colonoscopy/ flexible sigmoidoscopy/ 
CT- or MRT- colonoscopy – virtual colonoscopy – colonography/ capsule 
endoscopy/ DNA-analysis – genetic tests – laboratory tests – biomarker 
alone or in combination detect CRC in asymptomatic adult average risk 
populations early and positively influence the further course of CRC?” 
 
Table 2.1-1: PICO-question for CRC-screening report 
Population healthy adults OR risk groups/ healthy adults with family history in colon cancer 
Interventions 
early diagnosis 
(newer) faecal occult blood tests/FOBT 
colonoscopy 
flexible sigmoidoscopy 
capsule endoscopy 
CT- or MRT- colonoscopy/ virtual colonoscopy/ colonography 
DNA-analysis, genetic tests/testing 
laboratory tests/ biomarker 
Control interven-
tions 
natural history 
placebo 
all interventions see above 
Outcomes 
colon carcinoma mortality 
colon carcinoma, no/less invasive surgery 
screening harm(s) OR adverse outcomes OR adverse advents OR bleeding OR 
haemorrhage OR perforation OR bowel perforation(s) OR procedural complica-
tion(s) OR surgery OR admission to hospital OR sedation related event(s) OR 
chemical colitis OR infection(s) OR death 
Study design only HTA, systematic reviews, meta-analysis 1999-2009 
 
The search was limited to secondary literature (health technology assess-
ments, systematic reviews, meta-analyses) published from 1999-2009. The 
following databases were searched: 
Primary Databases: HTA, DARE, EED, Cochrane (NICE, CADTH, 
AHRQ, DIMDI), EuroScan 
Secondary Databases: Medline, EmBase 
                                                             
7 PICO: Patient, Population or Problem / Intervention or exposure / Comparison Intervention/ Out-
come 
PICO question for 
literature search 
 
 
search limited to 
secondary literature 
published from 1999-
2009 
Screening for Colorectal Cancer 
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This systematic search yielded 242 results. When three recent and reliable 
HTA-reviews (Health Council of the Netherlands, 2009, Ontario Health 
Technology Assessment Committee, 2009, United States Preventive Services 
Task Force, 2008) were identified, covering the evidence at least until the 
end of 2007, the search was narrowed to sources published thereafter, i.e. in 
2008, 2009. Of the initial 242 results 33 remained. Of these 2 articles were 
duplicates, after their removal 31 articles remained 
 
The abstracts of these 31 articles were reviewed independently by two re-
searchers. Disagreements about inclusion were resolved through discussion 
and consensus. 18 were excluded on the basis of their abstracts as not rele-
vant for the PICO-question of this report. The remaining 13 articles were in-
cluded in the analysis for this report. These 13 references are marked with a 
star (*) in the list of references at the end of this report. 
 
Due to a special interest in recent developments in the field of molecular 
screening-tests expressed by the Swiss cancer league, the above systematic 
search for secondary literature was supplemented by a small, unsystematic 
search for primary literature on new molecular screening-tests: 
 Medline: Gen*tests OR Biomarker AND Colon Cancer AND Screen-
ing; limits: RCT, CT 
 Google: “Gentest” and the above 
This unsystematic search yielded 3 articles, all of which were included. 
These 3 references are marked with two stars (**) in the list of references at 
the end of this report. 
Both searches were supplemented with an initial hand search for topic spe-
cific primary articles informing on details of issues covered in this report. 
These references can be found in appendix B together with a brief descrip-
tion. 
In the course of the compilation of this report further references were in-
cluded. 
2.2 Update literature search and inclusion 
Nov. 2010 
Following a request from the Swiss cancer league an update search of the lit-
erature was conducted on Nov. 12th 2010 adhering to procedure detailed 
above. 
 
This systematic update search yielded 46 results that were published in 2009 
and 2010 and had not been included in the results of the initial literature 
search in December of 2009. 
The abstracts of these 46 articles were reviewed – this time by the author 
alone. 43 were excluded on the basis of their abstracts as not relevant for the 
PICO-question of this report. In the end 3 results from the systematic litera-
after high-quality HTAs 
from 2008 and 2009 
were identified, search 
was narrowed to articles 
published thereafter 
(2008, 2009) 
additional unsystematic 
search on new 
molecular screening-
tests 
Update search with 
identical PICO question 
in Nov. 2010 
Systematic update 
search produced 3 
relevant articles 
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ture update search were included in the analysis for this report. These 3 ref-
erences are marked with three stars (***) in the list of references at the end 
of this report. 
 
Among these three references was a publication by the Canadian Agency for 
Drugs and Technologies in Health on the next generation of fecal DNA 
tests8. This reference addresses the special interest in recent developments 
in the field of molecular screening-tests expressed by the Swiss cancer 
league. 
In the course of the compilation of the update of the report further topic 
specific primary and secondary articles informing on details of issues cov-
ered in this report were included. To differentiate these articles in the refer-
ence list at the end of the document their Pubmed PMID is included. The 
most important of these was the publication of results of a multicentre ran-
domized controlled trial on once-only flexible sigmoidoscopy screening from 
the UK.9 
 
 
                                                             
8 Morrison, A. Next-generation fecal DNA tests – an evolving technology [Environmental Scan issue 7]. 
Ottawa: Canadian Agency for Drugs and Technolgies in Health; 2010 
9 Atkin (2010) 
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3 Appraisal of three core included HTAs 
The core of this report is based on three recent health technology assess-
ments/ systematic reviews by major health technology assessment or related 
institutions: Health Council of the Netherlands, United States Preventive 
Services Task Force and Ontario Health Technology Assessment Committee 
These three publications are appraised according to the PRISMA-statement 
on preferred reporting items for systematic reviews and meta-analyses in ta-
ble 3-1 below.10 
For a list of other recent relevant health technology assessments see appen-
dix A. 
 
 
 
                                                             
10 The PRISMA statement: Moher (2009), table 1, p. 266 
3 HTAs by Health 
Council of the 
Netherlands, USPSTF, 
Ontario HTAC form the 
core of report 
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Table 3-1: Appraisal of three core HTAs relied on for this report 
Institution Study Quality Appraisal 
PRISMA for SRs and MAs 
Comment 
Health Council of the 
Netherlands (2009) 
PRISMA checklist mostly not ful-
filled as report is not published as 
systematic review 
This advisory report to the Dutch Minister of Health, Welfare and Sport on whether and if, how to implement a na-
tional screening program is based on extensive literature and thorough evaluation of it. While not technically pub-
lished as a systematic review, the results and discussion sections are similar. The additional value of this report is the 
explicit program focus and the incorporation of data from several pilot programs specifically undertaken to inform 
the decision making process in the Netherlands. 
 
Publication bias was not assessed. 
Ontario Health Tech-
nology Assessement 
Committee  
OHTAC (2009) 
PRISMA checklist fulfilled except: 
section 1: report declared as “evi-
dence based analysis” not as “sys-
tematic review” 
section 2: structured abstract com-
pletely lacking 
section 12, 15, 19, 22: risk of bias in 
and across studies not extensively 
addressed 
point 27: role of funder in process of 
review not detailed 
 
United States Preven-
tive Services Task 
Force  
USPSTF 
(2008 und 2008a) 
PRISMA checklist fulfilled except 
section 12, 15, 19, 22 (risk of bias in 
and across studies) – compare com-
ment 
The review question was clear and supported by detailed inclusion criteria which are potentially reproducible. The 
search strategy included some relevant sources for published studies, but there was no apparent attempt to locate 
unpublished material. Publication bias was not assessed. Appropriate validity assessment tools were used to assess 
the quality of effectiveness and diagnostic studies. However, the results of this were not given in detail, making it 
difficult to verify the reported global assessment. The reported review process demonstrated attempts to minimize 
errors and bias. Heterogeneity was taken into account in the proposed methods of synthesis. The authors' conclu-
sions reflected the results from a small number of included studies. The conclusions are probably reliable, but under 
reporting in relation to study quality may warrant a cautious interpretation.11 
 
 
                                                             
11 from Database of Abstracts of Reviews of Effects (DARE), produced by the Centre for Reviews and Dissemination, University of York 
www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=12008106882 – accessed March 14th 2010 
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4 Results part I: Important facts about colorectal 
cancer-screening 
4.1 Colorectal cancer 
It is estimated that only 5% of all adenomas actually become malignant. The 
removal of these 5% of adenomas is sufficient to prevent CRC. The problem 
is that it is impossible to know which adenomas will become malignant and 
which will not. This inevitably results in a degree of over-diagnosis.12 In the 
case of most adenomas, removing them would have no effect on the survival 
of the individual concerned. The rates of over-diagnosis liable to result from 
CRC-screening cannot currently be quantified accurately.13 
Most CRC-patients (approximately 75-80%) have no close relatives who 
have previously suffered from this disease. This majority of cases are classi-
fied as ‘sporadic CRC’.14 
Approximately 20% of patients with CRC have some type of positive family 
history. For family-history CRC the lifetime risk of developing CRC de-
pends on the number of relatives with this cancer, their degree of kinship 
and the age at which CRC was diagnosed.15 Hereditary, genetically deter-
mined forms of CRC, i.e. Lynch syndrome – until recently referred to as he-
reditary non-polyposis colorectal carcinoma – and the various forms of poly-
posis are predisposed by genetical mutation and account for approximately 
5% of all cases of CRC.16 Individuals with Lynch syndrome are germ-line 
mutation carriers. They have a 25-70% lifetime risk of CRC. In people suf-
fering from familial adenomatous polyposis that risk is virtually 100 %.17 
For these hereditary, genetically determined forms of CRC-syndromes the 
issues involved in identifying candidates at risk, genetic testing, diagnosis 
and management are different than in general CRC-screening.18 
The remainder of CRC-cases develops in persons who have predisposing in-
flammatory bowel disease.19 
More than 90% of all new CRC-patients were above 55 years of age in 
2009.20 Age and gender are the only effective risk factors in risk profiling 
prior to CRC-screening. The research literature contains reports of various 
attempts to develop a model for risk profiling. As yet, however, there are no 
usable, validated examples.21 
                                                             
12 Health Council of the Netherlands (2009) p. 32 
13 Health Council of the Netherlands (2009) p. 80 
14 USPSTF Whitlock (2008a) p. 3 and Health Council of the Netherlands (2009) p. 34 
15 Health Council of the Netherlands (2009) p. 34, Baglietto (2006), Butterworth (2006) 
16 Lynch (2003), Hampel (2005), USPSTF Whitlock (2008a) p. 3 
17 Health Council of the Netherlands (2009) p. 35 
18 e.g. Lynch (2009) 
19 USPSTF Whitlock (2008a) p. 3 
20 data for the Netherlands as example, Health Council of the Netherlands (2009) p. 33 
21 Health Council of the Netherlands (2009) p. 37 
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4.2 Polyp size and CRC-screening 
A colorectal polyp is a fleshy growth occurring on the lining of the colon or 
rectum. A subtype of polyps are adenomas, benign tumors of glandular ori-
gin. Adenomas can grow from many organs including the colon.22 
Without the benefit of biopsy results, referral to colonoscopy is based on 
polyp size. Referral thresholds of screen-detected lesions to colonoscopy are 
largely based on expert opinion rather than clinical outcomes.23 
Polyp size < 6mm: 80% of found abnormalities 
 consensus by most, but not all experts24: no referral required 
 risk of being malignant in screening-population 0.03-0.2% 
 
Polyp size 6-10 mm: small polyps 
 
 no consensus; necessity and benefit of removing small polyps is not 
clear25 
 data from large screening-studies: 3 – 9% are advanced neoplasia 
(composite outcome: adenocarcinoma/ invasive carcinoma/ CRC and 
advanced adenoma26) 
 there have been no prospective studies describing the natural his-
tory of advanced neoplasia, and no longitudinal studies have vali-
dated the clinical benefit of targeting advanced neoplasia in screen-
ing-populations27 
 On the basis of data on the natural course of small polyps, there is no 
reason why a “wait-and-see policy” should not be adopted. For in-
stance, a study involving the annual endoscopic surveillance of ‘small’ 
polyps found that, after 3 years, their average diameter even tended to 
decline slightly.28 
Polyp size >10mm: large polyps  
 consensus: should be removed 
 10-15% probability of being or becoming malignant 
 evidence that removal of large adenomas has a particularly marked 
impact on the incidence of CRC29 (caveat! – data on the reduction of 
CRC-incidence through colonoscopy and polypectomy rely on weak 
evidence30) 
                                                             
22 compare: www.wikipedia.org  
23 USPSTF Whitlock (2008) 
24 USPSTF Whitlock (2008) 
25 USPSTF Whitlock (2008a) p. 4 
26 e.g. USPSTF Whitlock (2008a) p. 2 
27 USPSTF Whitlock (2008a) p.6 
28 Hofstad (1996) cited in Health Council of the Netherlands (2009) p. 70 
29 Health Council of the Netherlands (2009) p. 80 
30 USPSTF Whitlock (2008a) p. 4 
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Unanswered questions remain about the natural history of adenomas under 
10mm and therefore about their clinical significance. Clarifying the risk as-
sociated with smaller polyps will be critical for estimating the true sensitiv-
ity and specificity of current and future CRC-screening methods that di-
rectly visualize lesions. 
Treatment costs for highly advanced stages of CRC (i.e. the very cases that 
screening can often prevent) are expected to rise sharply when the latest very 
expensive generation of chemotherapy agents is deployed. This increase in 
the cost of CRC treatment makes screening for CRC more cost-effective.31 
4.3 Measuring the outcome of CRC-
screening trials 
Screening aims to save lives, i.e. screening strives to reduce all-cause mortal-
ity. There are three commonly used measures for evaluating the impact of 
CRC-screening on a population’s health: ‘all-cause mortality’ directly and its 
surrogates, ‘disease-specific mortality’ and ‘detection rate’ – detection of ad-
vanced adenomas’ or more narrowly ‘detection of CRC’. 
The optimal outcome measure for screening-trials is all-cause mortality. 
This endpoint requires very large samples. Of all causes of death, CRC 
represents very roughly 3%, a small fraction.32 The best available evidence 
suggests that the effect size of CRC-screening is a 15% reduction of CRC-
mortality.33 Even if directly translated into a reduction of all-cause mortal-
ity, assuming CRC-screening would not induce additional mortality, the ef-
fect of CRC- screening would represent only approximately 0.45% of all-
cause mortality, a very small effect size to prove in a randomized controlled 
trial. When, as in this case, the disease-specific mortality is proportionally 
very low, only a very slight increase in non-cancer mortality is required to 
offset a reduction in cancer mortality and vice versa.34 As a result the neces-
sary sample size to give a study sufficient power would have to be 300,000 
per group in the case of CRC-screening.35 Studies of all-cause mortality that 
are sufficiently large to have the required precision would not be feasible in 
many situations.36 This leads to an unresolved dilemma: Presently there is 
no evidence from randomized controlled trials showing a reduction of all-
cause mortality through CRC-screening. This lack of high-grade evidence 
leads to two interpretations: On one side the lack of high-grade evidence 
may suggest caution about CRC-screening. On the other side the fear is ex-
pressed, that a number of truly effective cancer-screening tests will incor-
rectly be deemed ineffective if emphasis is given to all-cause mortality, be-
cause it is not generally feasible to do studies that are large enough to relia-
bly document the impact of screening on all-cause mortality.37 
                                                             
31 Health Council of the Netherlands (2009) p. 51 
32 US CRC-lifetime mortality rate 2.4%, females 3.3%, USPSTF Whitlock (2008a) 
33 Cochrane Systematic Review, Hewitson (2007) 
34 Black (2002) 
35 Church (2002) 
36 Gail (2002) 
37 Weiss (2002) 
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It has been assumed that disease-specific mortality is a good surrogate end 
point for all-cause mortality. Because fewer patients are required to provide 
adequate power, disease-specific mortality rather than all-cause mortality 
has been the accepted end point of screening-studies. Still, a decrease in all-
cause mortality should be the ultimate aim of screening-programs, whether 
measured directly or not. A death from a non-malignant cause is just as im-
portant as a cancer-related death.38 
 
Data on all-cause mortality has the additional advantage of being reliably 
and readily available. Disease-specific mortality data are obtained via the 
less reliable cause-of-death statistics. The most problematic bias in screen-
ing-studies is the so called “slippery linkage bias”.39 Screening-activity and 
cancer treatment can be associated with excess non-cancer mortality (e.g. car 
accidents after sedation for screening-colonoscopy, heart attack during 
CRC-surgery). If these deaths are not accurately linked to cancer-screening 
and cancer treatment, if “the link slips”, a cancer-screening or cancer treat-
ment-induced death is not recorded under disease-specific mortality and 
consequently makes screening or cancer-treatment appear more beneficial 
than it actually is. 
Where studies are too small (number of participants, length of follow-up) to 
detect CRC-screening impact on disease-specific mortality, it is often neces-
sary to use even weaker intermediate end points to approximate the desired 
screening-outcome of reduced all-cause mortality. In the case of CRC-
screening these intermediate endpoints are ‘detection of advanced adeno-
mas’ and ‘detection of CRC’. These two measures are often combined and re-
ferred to as ‘detection of advanced neoplasia’. The assumption would be that 
higher detection of advanced neoplasia translates into lower CRC-mortality. 
That is not always grounded in fact, as by no means all advanced adenomas 
become malignant. In the case of most adenomas, removing them would 
have no effect on the survival of the individual concerned. Including all ad-
vanced adenomas as relevant screening-yield causes the effect of screening to 
be overestimated. At the other end of the disease spectrum, late stage CRC is 
also included as relevant yield, while only a small number of such cases can 
be cured. This too tends to overestimate the effect of screening. The goal of 
screening is not simply to detect abnormalities, it is to reduce people’s risk 
of developing CRC and of dying from this disease.40 
4.3.1 Addressing uncertainties about screening-
outcome 
The introduction phase of a population based CRC-screening program is 
suggested as a setting for evidence generation at relatively little additional 
cost compared to setting up large clinical trials. Screening for CRC using 
any primary test modality is suggested to be launched in a public health 
program with randomization of the target population at the implementation 
phase. This experimental design is considered to be a prerequisite for evalu-
                                                             
38 Juffs (2002) 
39 Black (2002) 
40 Health Council of the Netherlands (2009) p. 32 
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ation of such a screening-program because the effectiveness of preventing 
deaths is likely to be small and results may otherwise remain inconclusive.41 
Establishing the net-effect of screening healthy people – only a few of whom 
can be helped, some of whom will be harmed, and most of whom will experi-
ence little effect – will often exceed the limits of medical science. Thus there 
is all the more reason for full disclosure of both what is known and what is 
unknown about screening for informed decision making.42 
4.3.2 Evidence required for introduction of new 
screening-test 
What is the situation when new tests emerge, while a screening-test that has 
been proven to be effective (such as gFOBT43) is already available? Guide-
lines for such situations have been drawn up on the basis of systematic re-
views of the literature together with a consensus approach involving experts. 
Studies to determine whether a new test is as good as or better than existing 
ones do not need to use disease-specific mortality as an end point again, pro-
vided that randomized screening-trials have demonstrated that the existing 
test reduces disease-specific mortality. The evaluation must involve a direct 
comparison of the old and new tests on the basis of ‘intention to screen’, a 
comparison in terms of uptake and yield, the evaluation must be conducted 
among the general population and followed by a cost-effectiveness analy-
sis.44 
4.4 Colonoscopy – final common pathway  in 
CRC-screening 
In contrast to the situation with most other screen-able diseases, there are 
several (first-line) screening-tests available for CRC. The methods differ in 
various ways, including the participation rate and the sensitivity. Colono-
scopy is the final common (second-line) pathway of all CRC-screening. 
                                                             
41 Malila (2008) 
42 Black (2002) 
43 Cochrane Systematic Review, Hewitson (2007) 
44 Health Council of the Netherlands (2009) p. 28 
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Figure 4.4-1: Colonoscopy as the final common pathway for CRC-screening 
*in practice CT-colonography is presently not recommended by any mayor health-
technology-assessment institution or medical society as a first-line test for popu-
lation-based CRC-screening 
Abbreviations: CT-C … computed tomography colonography 
 FOBT … faecal occult blood test 
 FS … flexible sigmoidoscopy 
Source: adapted from figure 4.4-1, Health Council of the Netherlands (2009) 
p. 13 
 
4.5 Characteristics of Colonoscopy 
In colonoscopy, a video-endoscope is used to examine the entire length of 
the colon. Extensive bowel preparation is required. Colonoscopy is often 
performed with the subject under conscious sedation. Depending on the re-
gionally established clinical practice, operator preference and setting (pri-
vate practice, hospital) colonoscopy is also performed without sedation. Co-
lonoscopy is considered the (imperfect) reference standard for detecting 
CRC and adenomas. Where technically possible, polyps are removed imme-
diately (polypectomy). If this is not possible, biopsies are taken. All retrieved 
lesions are evaluated histologically. In this respect colonoscopy stands out in 
potentially being at once a screening, diagnostic and therapeutic interven-
tion. Some screening-programs use colonoscopy as a first-line screening-
method. With all screening-methods, if any abnormalities are detected, the 
patient is referred for colonoscopy. Colonoscopy is the final common path-
extensive bowel 
preparation required 
polyps can be removed 
immediately 
colonoscopy at once 
screening, diagnostic 
and therapeutic 
intervention 
Results part I: Important facts about colorectal cancer-screening 
LBI-HTA | 2010 23 
way of all CRC-screening. With advancing age and coexisting conditions the 
risk associated with colonoscopy increases. At the same time the benefit di-
minishes because of shorter life expectancy.45 This is the rationale behind 
setting upper age limits for CRC-screening. 
Two aspects limit colonoscopy as a perfect gold standard for CRC and ade-
noma detection. Endoscopic methods are operator and technology depend-
ent.46 Accuracy is highly dependent on the quality of the bowel preparation 
and endoscopic examination.47 Inter-examiner differences in detection of 
polyps have been shown in population-based studies of screening-
colonoscopy.48 The examiners’ skill and care in examining the colon (com-
pleteness of colonoscopy, withdrawal time) vary greatly. Repeated colono-
scopy or colonography by means of computed tomography performed in 
close succession to colonoscopy can identify neoplastic lesions that were not 
detected during the initial procedure.49 These important missed lesions in-
clude adenomas greater than 10 mm in diameter.50 Both polyp-yield51 and 
complication rate52 vary by a factor of up to ten between examiners. 
Though evidence on the magnitude of overall protection from CRC accord-
ing to anatomical site through colonoscopy performed in the community set-
ting is sparse, the association of colonoscopy with fewer deaths from CRC is 
primarily limited to deaths from cancer developing in the left side of the co-
lon (distal cancer).53 There is evidence from Germany, Canada and the US 
that colonoscopy is less effective for right-sided (proximal) CRC than-left 
sided (distal) cancer.54 There is evidence that the prevalence of left-sided 
(distal) but not of right-sided (proximal) advanced adenomas is reduced 
within a 10-year period after colonoscopy.55 Why would colonoscopy be less 
effective in preventing death from right-sided (proximal) CRC? First, some 
supposedly “complete” colonoscopies in practice do not actually evaluate the 
entire right (proximal) colon all the way to the cecum. Second, bowel prepa-
ration may be worse in the right (proximal) colon. Finally, right-sided (prox-
imal) and left-sided (distal) colonic neoplasia may differ biologically. Right-
sided (proximal) colonic adenomas are less often pedunculated and are occa-
sionally flat, which makes them harder to identify and remove. The histol-
ogy and molecular features of right-sided (proximal) cancer may differ, im-
plying predominant genetic pathways of carcinogenesis, which may influ-
ence the effectiveness of early detection. Differences in tumor biology may 
limit the potential to prevent right-sided (proximal) CRC-death with cur-
rent endoscopic technology.56 Data from the US demonstrate a right-sided 
(proximal) migration of CRC over the past two decades, which is attributed 
                                                             
45 e.g. Lieberman (2009) 
46 e.g. Lieberman (2009) 
47 USPSTF Whitlock (2008) 
48 e.g. Barclay (2006) 
49 e.g. Barclay (2006) 
50 e.g. Lieberman (2006) 
51 e.g. Barclay (2006) 
52 e.g. Pignone (2000) 
53 e.g. Baxter (2009), Brenner (2010) 
54 e.g. Baxter (2009) 
55 e.g. Brenner (2010) 
56 e.g. Baxter (2009) 
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to a decrease in incidence of left-sided (distal) CRC and an aging population 
in which right-sided (proximal) lesions are more common.57 
Estimating the sensitivity and specificity for screening-colonoscopy in a real 
life environment from the available evidence is even more challenging than 
for diagnostic colonoscopy, where the data situation is better. Most available 
studies for screening-colonoscopies have selected practitioners who were 
quite experienced and not necessarily representative of community practice. 
No tandem colonoscopy studies evaluated average-risk populations.58 
Randomized trials studying the effect of colonoscopy on the incidence of or 
the mortality due to colorectal cancer have not been conducted. Recom-
mended guidelines are based on statistical prediction models and case–
control studies. Recent estimates suggest that colonoscopy has a lower effect 
on mortality associated with colorectal cancer than previously thought, and 
researchers have warned that overly optimistic claims about its benefits have 
been used to sell colonoscopy to the general public.59 
4.6 Evidence on CRC-screening tests 
The evidence base from large trials on the effectiveness of different first-line 
screening tests for CRC is very limited. 
 guaiac faecal occult blood test or gFOBT – 4 randomized controlled 
trials (RCTs), disease-specific CRC mortality: relative risk reduction 
(RRR) 15%, no impact on all-cause mortality60. For trial results on 
gFOBT compare table 4.7-1 below. 
 immunochemical faecal occult blood test or iFOBT: 1 RCTs in re-
cruiting phase61 - results in 10+ years 
 molecular markers: none 
 colonoscopy: none, 2 RCTs in recruiting phase62 – results in 10+ 
years 
                                                             
57 USPSTF Whitlock (2008a) 
58 USPSTF Whitlock (2008a) p. 12 
59 Betthauer (2009) p. 301 
60 Cochrane Systematic Review, Hewitson (2007) 
61 Barcelona, Spain: Colorectal Cancer Screening in Average-Risk Population: Immunochemical Fecal 
Occult Blood Testing Versus Colonoscopy 
Trial registered at www.ClinicalTrials.gov with registration no: NCT00906997 
62 Barcelona, Spain: Colorectal Cancer Screening in Average-Risk Population: Immunochemical Fecal 
Occult Blood Testing Versus Colonoscopy 
Trial registered at www.ClinicalTrials.gov with registration no: NCT00906997 
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 flexible sigmoidoscopy: a large multicenter RCT in UK63 showed for 
disease specific CRC mortality a RRR of 31% and a decline in CRC 
incidence of 23%. Intermediate results after a shorter follow up from 
an RCT in Norway64 showed no influence on CRC mortality [two 
more trials in Italy65 and USA66 to publish results fairly soon, Norwe-
gian study to publish updated results with longer follow-up] - For 
more detailed trial results on flexible sigmoidoscopy compare table 
4.7-5 below. 
 CT-colonoscopy: none 
 
 “Randomized trials have been a long-standing requirement for the intro-
duction of new drugs to the market. It is difficult to understand why the 
standard of evidence should be lower for diagnostic tools or screening 
tests.”67 
4.7 Characteristics of different CRC-
screening tests 
Table 4.7-1: Characteristics of commonly used CRC-screening tests 
Test CRC inci-
dence re-
duction* 
CRC mortality 
reduction * 
Screening 
interval 
Invasiveness 
and prepared-
ness 
gFOBT none 15% short (an-
nually, bi-
enially) 
none 
Flexible 
Sigmoid. 
23%(UK)68 
none(NO)69 
27-31%(UK)70 
none(NO)71 
long (5-10 
years) 
invasive; en-
ema bowel 
cleansing 
Colon-
oscopy 
Unknown unknown long (at 
least 10 
years) 
invasive; oral 
bowel clean-
sing 
* Figures for intention-to-screen analyses observed in randomised trials 
Source: Bretthauer (2010) p. 1260 
                                                             
63 UK: once only sigmoidoscopy, Atkin (2010) 
64 once only sigmoidoscopy, NORCCAP trial, preliminary results after only 7 years of follow up: Hoff 
(2009) – NORCCAP is the only study of flexible sigmoidoscopy screening that is truly population 
based and will provide an estimate for effectiveness after 10 years of follow-up in 2013) 
65 Italy: once only sigmoidoscopy, SCORE, Segnan (2002) 
66 USA: sigmoidoscopy every 3-5 years, PLCO, Weissfeld (2005) – results in peer-review process, per-
sonal e-mail correspondence with Prof. Weissfeld, Nov. 2010 
67 Betthauer (2009) p. 301 
68 findings after 11 years of follow-up from the UK: Atkin (2010) 
69 preliminary findings from the NORCCAP trial after only seven years of follow-up: Hoff (2009) – 
NORCCAP will provide an estimate for effectiveness after 10 years of follow-up in 2013 
70 findings after 11 years of follow-up from the UK: Atkin (2010) 
71 preliminary findings from the NORCCAP trial after only seven years of follow up: Hoff (2009) 
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No current CRC-screening tests are without drawbacks, including potential 
harms, limited accessibility or imperfect acceptability to patients.72 The dif-
ferent CRC-screening tests are briefly described below. Details about their 
characteristics can be found in tables 4.7-1 to 4.7-7 thereafter. 
 
FOBTs 
Both guaiac or gFOBT and immunochemical or iFOBT are based on the 
principle of detecting blood traces in faeces, hence the name faecal occult 
blood test FOBT. 
1. gFOBT 
This test method has been used for around 40 years. Most chemical FOBTs 
make use of guaiac gum, which is extracted from the hardwood tree guaia-
cum officinale (gFOBT). Guaiac oxidizes when in contact with hydrogen pe-
roxide, resulting in an unstable color change which has to be visually as-
sessed by a person. This reaction is catalyzed by haem, a component of hae-
moglobin common to all species. The test is not specific for human blood 
and can generate false positive and false negative results due to peroxidase 
reactions (and their inhibitors) in food products, such as red meat. gFOBTs 
low sensitivity means that two samples must be collected from each of three 
consecutive stools, six samples in total. This renders gFOB-testing laborious 
for the screening-participant and not particularly user-friendly.73 The result 
is a relatively low participation rate in gFOBT-screening. 
The first efficacy trials (RCTs) conducted in the realm of CRC-screening 
were based on the guaiac (gFOBT) Haemoccult II test. Four RCTs with a to-
tal of 320,000 participants were conducted between 1995 and 2002 with fol-
low-up of 8-18 years, showing a relative risk reduction in CRC-specific mor-
tality of 15 % while no impact on all-cause mortality was found.74 This 
makes gFOBT the CRC-screening method with the largest RCT base dem-
onstrating effectiveness. For more information on gFOBT compare table 4.7-
1 below. 
                                                             
72 USPSTF Whitlock (2008a) p.6 
73 Health Council of the Netherlands (2009) p. 43 
74 RCTs in Gothenberg, SWE; Funen, DK; Nottingham, UK; Minnesota, US; Cochrane Systematic Re-
view, Hewitson (2007) 
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2. iFOBT 
More recently a test method has been developed, which involves the immu-
nological analysis of faecal samples for occult blood (iFOBT). These tests are 
specific for human blood. The subject only has to provide a single faecal 
sample, positively affecting participation rate. Analysis of quantitative 
iFOB-testing can be automated, thus increasing quality control and reduc-
ing cost. There is micro flora in stool that can degrade the biomarker or 
hamper analysis. This problem becomes more pronounced the longer it 
takes for the stool sample to be analyzed and the higher the temperature the 
sample is exposed to during that time. Special precautions need to be taken 
to optimize the test-process in practice from stool-sampling at home to anal-
ysis in a laboratory. 
In terms of sensitivity, the benefit of iFOBT relative to gFOBT lies primar-
ily in the detection of early CRCs and advanced adenomas, which involve 
less bleeding than later stage CRC. This means that iFOBT-screening can be 
expected to have a greater effect on cancer incidence and mortality than 
gFOBT-screening. At equal specificity, iFOBT is more sensitive than 
gFOBT.75 For more information on iFOBT compare table 4.7-2 below. 
3. Molecular markers 
The basis of CRC is a disturbance of the biological processes in the intesti-
nal epithelial cells, particularly resulting from (generally non-hereditary) 
changes in the way that certain oncogenes and tumor suppressor genes func-
tion. This disturbance is accompanied by changes in the molecular structure 
or quantity of substances such as DNA, RNA and protein. By means of labo-
ratory tests, it is possible to measure molecules of these substances – referred 
to in this context as ‘biomarkers’ – in samples of stool, blood or tumor tissue. 
Research in this field is aimed at the identification and large-scale valida-
tion of biomarkers with better test characteristics, and optimization of the 
relevant test methodologies.76 
3.1 Biomarkers in stool 
3.1.1 DNA markers in stool 
When faeces pass a tumor during progression through the 
bowel, tumor cells or cell remnants are entrained. The ex-
creted faeces therefore contain tumor DNA, which can be 
detected by testing.77 
 
The technical challenges that compromised first-, second- 
and third-generation versions of the fecal DNA tests are 
being addressed. Refinements in recent laboratory meth-
odologies, additional improvements of panel biomarkers 
that maximize sensitivity and specificity for both advanced 
adenomas and cancer, and cost modifications are emerg-
ing. If DNA fecal testing can improve compliance and re-
duce unnecessary diagnostic follow-up compared with 
FOBT’s, cost savings may be realized. In addition, the 
demonstration of mortality benefit in clinical trials, evi-
                                                             
75 Health Council of the Netherlands (2009) p. 47 
76 Health Council of the Netherlands (2009) p. 73 
New candidates for CRC-screening tests are of particular interest to the initiator of this report. This is 
the reason for the amount of space allocated to the molecular markers. 
77 Health Council of the Netherlands (2009) p. 74 
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dence to assess the sensitivity and specificity of fecal DNA 
tests, and verification of optimal screening intervals are 
necessary before fecal DNA testing can be used as a CRC 
detection tool in average risk screening populations.78 
 
 
3.1.2 RNA markers in stool 
Faecal RNA has also been investigated as a possible CRC-
biomarker.79 
3.1.3 Protein markers in stool 
iFOBT is in fact a test for the presence of a protein (glo-
bin) in stool. Using the same principle, it should be possi-
ble to test for tumor-specific proteins.80 One example is 
the enzyme M2-PK. 
 
 
 
3.2 Biomarkers in blood 
For many people, giving a blood sample is less inconvenient than providing 
a faecal sample. There is no micro flora which could degrade the biomarker 
or hamper analysis like in stool. Also sample processing may be easier.81 
3.2.1 DNA markers in blood 
DNA is not broken down as quickly in blood as in faeces, 
and blood contains less PCR82 inhibitory factors.83 One 
example is circulating methylated84 mSEPT9 DNA in 
plasma. 
3.2.2 RNA markers in blood 
3.2.3 Protein markers in blood 
A systematic review of blood markers for early detection of CRC found the 
evidence thus far restricted to single studies with limited sample size and 
without further external validation.85 The authors conclude that larger pro-
spective studies using study populations representing a screening-
population were needed to verify promising results. In addition, future stud-
                                                             
78 Morrison (CADTH) (2010) p. 3 
79 Health Council of the Netherlands (2009) p. 74 
80  Health Council of the Netherlands (2009) p. 75 
81 Hundt (2007) 
82 compare: www.wikipedia.org 
Polymerase chain reaction (PCR) is a technique to amplify a single or few copies of a piece of DNA 
across several orders of magnitude, generating thoUSnds to millions of copies of a particular DNA 
sequence.  PCR is now a common and often indispensable technique used in medical and biological 
research labs for a variety of applications. These include the diagnosis of hereditary diseases and the 
detection and diagnosis of infectious diseases. 
83 Health Council of the Netherlands (2009) p. 75 
84 compare: www.wikipedia.org 
DNA-methylation, a modification of DNA (as opposed to a genetic mutation) contributes to epigenetic 
inheritance. 
85 Hundt (2007) 
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ies should pay increased attention to the potential of detecting not only CRC 
but precursor lesions, due to their value for CRC-screening.86 
One of the pilot projects set up in preparation for the decision whether – 
and if, how – to initiate a population-based screening-program in the Neth-
erlands aims to develop molecular screening-tests and molecular diagnostics 
for customized therapy. The main thrust of the approach is to translate re-
cent discoveries about the molecular biology of CRC into new laboratory 
tests and new applications for diagnostic imaging. Existing biomarker tests 
are validated in a screening-population. 87 Similar initiatives also involving 
academia-industry cooperation are under way in other countries.88 
Summing up, it is reasonable to believe that in the long term a screening-
program could be enhanced by the use of molecular markers.89 It is expected 
to be another 5 years before suitable ones can be identified.90 Then it will be 
necessary to conduct research in unselected populations to establish whether 
biomarker-based screening-offers any advantages over the existing methods. 
This will take at least another 5 years. It would not be appropriate to intro-
duce a new screening-test until its superiority to the existing test had been 
demonstrated in randomized trials. Such studies can be undertaken effi-
ciently in the context of ongoing screening-activities.91 Furthermore, model-
ling taking participation rates into account would need to show that the new 
test was more efficient than existing screening. For more information on 
molecular markers under development for CRC-screening – including MP-
2K and m9SEPT as specific examples – compare table 4.7-3 below. 
Methods visualizing the colon 
Endoscopic methods 
4. Colonoscopy as first-line screening-test 
Although colonoscopy is generally safe, it is still an invasive procedure with 
a 0.2% rate of serious complications — ten times higher than for any other 
commonly used cancer screening test. Repeated examinations over time may 
incur a substantial cumulative rate of complications, not even counting 
hard-to-detect complications (if they occur), such as silent myocardial in-
farction.92 
                                                             
86 Hundt (2007) 
87 Health Council of the Netherlands (2009) p. 25 
88 e.g. Germany, compare http://www.innovations-
re-
port.de/html/berichte/biowissenschaften_chemie/darmkrebs_erkennen_bevor_entsteht_133139.html 
accessed March 14th 2010 
89 Health Council of the Netherlands (2009) p. 76 
90 Health Council of the Netherlands (2009) p. 81 
91 Health Council of the Netherlands (2009) p. 76 
92 Ransohoff (2009) 
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The evidence on complication rates after screening-colonoscopy compared to 
symptomatic colonoscopy is unconclusive. Some of it suggests that compli-
cation rates of screening-colonoscopies are lower than of diagnostic and the-
rapeutic colonoscopies performed in symptomatic patients according to 
some sources.93 The argument there is that individuals participating in 
screening are on average younger and in better health than symptomatic pa-
tients. CRC-screening stands out from screening for other diseases. 
Recent research finds complications after colonoscopies two to three times 
higher than previously estimated. Also more complications happen after 
screening colonoscopy than symptomatic colonoscopy: 94 
Procedure related hospital visits within 14 days of the procedure occurred in 
0.84% of colonoscopies and in 0.95% of screening colonoscopies. Most events 
were not captured by standard reporting. The complication rate might in re-
ality be higher since only complications treated at the studied hospital were 
recorded and not in neighbouring ones. The most common complications 
were abdominal pain (47%), gastrointestinal bleedings (12%) and chest pain 
(11%). The cost of unexpected hospital visits post endoscopy may be signifi-
cant and should be taken into account in screening and surveillance pro-
grams. Also strategies for automating adverse event reporting should be de-
veloped. 
A systematic review of perforation and mortality of colonoscopy found no 
differences in complication rates between screened populations versus pa-
tient populations:95 The overall perforation rate of colonoscopy (higher for 
colonoscopies with polypectomy than for those without) was 66 per 100.000, 
the overall mortality rate 6 per 100.000. 
No other screening-test – e.g. PAP for cervical cancer and mammography for 
breast-cancer – has comparable rates to colonoscopy of serious adverse com-
plications, including death, through the testing itself. In this sense colono-
scopy is unprecedented for a screening-test recommended for use in the gen-
eral population.96 For more information on colonoscopy as a first-line 
screening-test compare table 4.7-4 below. 
5. Flexible sigmoidoscopy 
Flexible sigmoidoscopy is a visual examination using an endoscope inserted 
through the anus into the distal (left-side) portion of the large intestine. 
There are fewer complications than with colonoscopy. Flexible sigmoido-
scopy needs only limited bowel preparation compared to colonoscopy or 
capsule endoscopy. For flexible sigmoidoscopy an enema is required prior to 
the examination. Biopsies may be taken during the procedure. A removal of 
polyps is possible.97 Inter-examiner differences in the detection of polyps 
have been shown in population-based studies of screening-flexible sigmoido-
scopy.98 Recently the results of a large multi center randomised controlled 
trial of once only flexible sigmoidoscopy screening have been published in 
the UK:99 After over eleven years of follow-up it finds a decline in disease 
specific mortality of 31% and a reduction in CRC- incidence of 21%. 
                                                             
93 e.g. Niv (2008) 
94 Leffler (2010) 
95 Van Heijningen (2010) 
96 Baxter (2010) 
97 e.g. Atkin (2010) 
98 e.g. Barclay (2006) 
99 Atkin (2010) 
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“The UK trial illustrates the value of long term publicly funded medical re-
search. The study was designed in the early 1990s, and the main results are 
available almost 20 years later. Many people argue that medicine is develop-
ing so rapidly that a trial of this duration would be outdated by the time the 
results are available. This landmark study shows that this is a false assump-
tion. It is important that large funding organizations like the UK National 
Health System, the European Union, and others support long term clinical 
trials that tackle important health problems beyond the often short term 
scope of industry funded medical research.”100 
The previous intermediate results from a Norwegian sigmoidoscopy trial 
found no influence on disease specific mortality.101 
Colorectal cancer screening guidelines usually recommend flexible sigmoi-
doscopy with a five year screening interval. In light of the UK trial, longer 
screening intervals should be recommended.102  
Adequately trained nurse practitioners can undertake FS as competently as 
can gastroenterologists and public acceptance of nurse led flexible sigmoido-
scopy is high.103 
The UK trial104 provides valid and robust evidence for the efficacy of flexi-
ble sigmoidoscopy screening. The effectiveness of such screening in the gen-
eral population is still uncertain, however, because the UK trial excluded 
people who did not explicitly express their wish to be randomized. NORC-
CAP105 is the only study of flexible sigmoidoscopy screening that is truly 
population based and will provide an estimate foreffectiveness after 10 years 
of follow-up in 2013.106 
 
For more information on flexible sigmoidoscopy compare table 4.7-5 below. 
6. Capsule Endoscopy 
Capsule endoscopy is a technique in which the subject swallows a capsule 
that takes photographs at regular intervals while it travels through the large 
bowel.107 These images are transferred wirelessly to an external receiver, 
which is worn by the individual being examined. After 24 hours, the data ac-
cumulated by the receiver is downloaded and the images are examined on a 
monitor. At the end of the examination period the capsule is ejected from 
the body with the faeces. The rate of detection of polyps is dependent on the 
skills of the examiner. Extensive bowel preparation is needed. Biopsy or re-
moval of polyps is not possible. 
With the capsule’s relatively low sensitivity for the detection of colorectal le-
sions, its requirement for more extensive bowel-cleansing regimens as com-
pared with colonoscopy and CT colonography, and its high cost, colon cap-
                                                             
100 Betthauer (2010) p. 1260 
101 preliminary findings from the NORCCAP trial after only seven years of follow-up: Hoff (2009) – 
NORCCAP will provide an estimate for effectiveness after 10 years of follow-up in 2013 
102 Betthauer (2010) p. 1260 
103 Atkin (2010) 
104 Atkin (2010 
105 Hoff (2009) 
106 Bretthauer (2010) 
107 Health Council of the Netherlands (2009) p. 65 
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sule endoscopy cannot be recommended [for cancer screening] at this time. 
108 
For more information on capsule endoscopy as a first-line CRC-screening 
test compare table 4.7-6 below. 
Virtual endoscopic methods 
7. Colonography 
Colonography or “virtual colonoscopy” involves examination of the entire 
large intestine by means of CT- or MRI-scanning, preferably after limited 
bowel preparation (1-day low-fiber diet, oral contrast agent for the uniform 
staining of stool residue and moisture). To achieve colonic distension carbon 
dioxide is delivered via a rectal catheter. Examinations are performed in 
both supine and prone position. Biopsy or removal of polyps is not possible. 
The challenges of adequately ensuring high-quality CT-colonography read-
ings are illustrated by reports that half of the radiologists did not pass the 
initial certifying examination after 1.5 days of training or experience with 
more than 500 cases.109 Complications tend not to be serious. In the case of 
CT-colonography exposure to ionized radiation is a problem 
Extra-colonic findings during CT-colonography are an issue. Evaluation of 
images generated during CT-colonography also involves findings of struc-
tures outside the colon itself. This might be an advantage, in the case of se-
rious, treatable disorders, but it can also be a disadvantage. Among the tar-
get group for population-screening, the chance that a serious, treatable dis-
ease will be found is quite small. Moreover, screening may reveal disorders 
such as an aneurysm of the aorta, for which the usefulness of early detection 
is by no means a foregone conclusion. What is clear, however, is that the re-
porting of extra-colonic abnormalities can double the number of referrals for 
diagnosis.110 The use of low radiation dosage reduces image quality outside 
the colon and is expected to significantly reduce the number of referrals due 
to extra-colonic findings after screening with CT-colonography.111 For more 
information on CT-colonography as a first-line CRC-screening test compare 
table 4.7-7 below. 
Given potential harms and observed variability in test accuracy, emphasis on 
quality standards für implementation of any operator-dependent CRC-
screening test appears prudent.112 
 
 
                                                             
108 Betthauer (2009) p. 300 
109 USPSTF Whitlock (2008) 
110Health Council of the Netherlands (2009), p. 68 
111 Health Council of the Netherlands (2009), p. 68 
112 USPSTF Whitlock (2008) 
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Table 4.7-1: Detailed characteristics of gFOBT as CRC-screening test 
Test Evidence 
on 
effectiveness 
 
Expected par-
ticipation rate 
Number of re-
sulting colono-
scopies 
Sensitivity of 
test 
Specificity of 
test 
Information 
1. 
gFOBT 
4 RCTs 
 
1975-2002 
 
follow-up: 
8-18 years 
 
320,000 participants 
 
disease-specific CRC-
mortality: 
RRR 11-18% 
 
no impact on all-cause 
mortality found 
low 
 
around 50% 
 
47-50% 
in NL trials 
 limited 
 
HCII test-
sensitivity: 
CRC 
13-38% 
 
HCII biennial 
program sensi-
tivity: 
CRC 
50-60% 
CRC 
99% 
 
PPV for ad-
vanced neopla-
sia: 
50% 
 laborious and user unfriendly: two samples each on three consecutive 
stools necessary 
 negative impact on participation 
 test is not specific for human blood and can generate false positive 
and false negative results due to peroxidase reactions (and their in-
hibitors) in food products, such as red meat 
 dietary measures necessary before test 
 medication use can influence test (vitamin c, aspirin etc.) 
 color change unstable, has to be visually assessed 
 reader dependence 
COMPLICATIONS 
 gFOBT: no studies exist113, assumption: none 
 follow up-colonoscopy, see Table 4.7-4 
Abbreviations: C … colonoscopy 
CE … capsule endoscopy 
 
HCII … hemoccult II test 
 
 CI … confidence interval iFOBT … immunochemical FOBT NordICC … The Nordic-European Initiative on Colorectal 
 CRC … colorectal cancer ITA … Italy Cancer 
 CT-C … computed tomography-colonography mm … millimeters PPV … positive predictive value, percentage of true positives among test po-
sitives 
 DNA … deoxyribonucleic acid NL … Netherlands RCT … randomized controlled trial 
 FOBT … faecal occult blood test 
FS … flexible sigmoidoscopy 
NL-CoCoS … Population screening for colorectal 
cancer by colonoscopy or CT-colonography in the 
Netherlands 
RNA … ribonucleic acid 
RRR … relative risk reduction 
 gFOBT … guaiac faecal occult blood test NNScope … number needed to scope UK … United Kingdom 
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
                                                             
113 USPSTF Whitlock (2008) 
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Table 4.7-2: Detailed characteristics of iFOBT as CRC-screening test 
Test Evidence 
on 
effectiveness 
Expected par-
ticipation rate 
Number of re-
sulting colono-
scopies 
Sensitivity of test Specificity of 
test 
Information 
2. 
iFOBT 
little data available on 
regularly repeated 
iFOBT-screening 
 
1 study found CRC-
mortality: 
RRR 32% 
(because of cluster 
randomization me-
thodically problematic) 
 
numerous observa-
tional studies 
60-62% 
in NL trials 
35/1,000 
 
assuming par-
ticipation rate 
of 60% and re-
ferral threshold 
of 75ng/ml 
higher than 
gFOBT 
 
estimates show 
variability within 
each test, possibly 
because of differ-
ent collection 
methods, refer-
ence standards114 
 
depending on re-
ferral threshold 
and specific test 
 
test-sensitivity: 
CRC 
55-90% 
lower than 
gFOBT 
 
depending on 
referral thresh-
old and specific 
test 
 
PPV for ad-
vanced neopla-
sia: 
33% 
 more false positives than gFOBT 
 for screening-participants more user friendly sampling, more reliable, 
more hygienic than gFOBT 
 positive impact on participation 
 iFOBT detects more early CRCs and advanced adenomas, which in-
volve less bleeding than later stage CRC, than gFOBT 
 iFOBT-screening can be expected to have a greater effect on can-
cer incidence and mortality 
 at equal specificity, iFOBT is more sensitive than gFOBT 
 some iFOBTs are quantitative in nature 
 adjusting threshold enables screening to be more focused and 
cost-effective 
  automated testing (reader independent, cheaper) 
 no data available concerning an optimum referral threshold to C  
test characteristics of screening dependent on it: the lower the 
threshold 
 the higher the sensitivity 
 the higher the number of participants who have to be referred 
to C 
 the higher the number of false positives (i.e. the lower the 
specificity) 
 no convincing evidence to suggest that iFOBT-screening is less effec-
tive in detecting proximal tumors 
 no clear evidence of adverse risk selection (in which fewer individuals 
from high-risk groups participate) as is the case with cervical-cancer 
screening 
 iFOBT yields better participation rates, detection rates and is signifi-
cantly more cost effective than gFOBT-screening (NL trials) 
COMPLICATIONS 
 iFOBT: no studies exist115, assumption: none 
 follow up-colonoscopy, see Table 4.7-4 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
 
                                                             
114 USPSTF Whitlock (2008) 
115 USPSTF Whitlock (2008) 
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Table 4.7-3: Detailed characteristics of molecular markers as CRC-screening test 
Test Evidence 
on 
effectiveness 
 
Expected 
participation 
rate 
Number of 
resulting co-
lono-scopies 
 
Sensitivity of 
test 
Specificity of 
test 
Information 
3. 
Molecular mark-
ers 
 
numerous candidate bio-
markers 
 
development of practical tests 
ongoing 
 
large-scale validation studies 
required thereafter 
    biomarkers: DNA, RNA, proteins in faeces, blood or tumor tissue 
 clinical accuracy data on faecal DNA tests is still too limited to support 
population-screening116 
 mismatch between available clinical studies on faecal DNA tests and 
commercially available tests117 
 biomarkers do not yet constitute a realistic alternative to FOBT 
 progress is being made with development of numerous candidate bio-
markers118 
 development of practical tests will require the involvement of compa-
nies capable of marketing the tests 
 further development work will focus exclusively on markers over 
which intellectual property rights have been secured 
3.1.3 
 
faecal M2-PK (en-
zyme) 
evidence on detecting precur-
sors to CRC scant and contro-
versial119 
 
one large study among 1,082 
screening-participants in Ger-
many 120 
 
one study prospectively com-
paring office-based iFOBT and 
M2-PK in 600 subjects above 
average risks121 
  cut-off 4U/ml 
 
advanced ade-
nomas: 
22%122 
 
other adeno-
mas: 
23%123 
 
CRC and large 
adenomas 
>10mm: 
72,4%124 
cut-off 4U/ ml 
 
82%125 
 
CRC and large 
adenomas 
>10mm: 
73,8%126 
 tumor M2-PK is an isoform of the glycolytic enzyme PK, which is over 
expressed in proliferating cells such as tumor cells 
 test has been proposed for early detection of CRC 
 test has only very limited potential to distinguish between people bear-
ing precursors to CRC and people with no finding at C127 
 poor performance characteristics demonstrated do not certify further 
use as a screening-tool in CRC and large adenomas128 
                                                             
116 USPSTF Whitlock (2008a) 
117 USPSTF Whitlock (2008a) 
118 e.g. Morrison (CADTH) (2010) 
119 Haug (2008) 
120 Haug (2008) 
121 Shastri (2008) 
122 Haug (2008) 
123 Haug (2008) 
124 Shastri (2008) 
125 Haug (2008) 
126 Shastri (2008) 
127 Haug (2008) 
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3.2.1 
 
methylated SEPT9 
DNA in blood 
plasma 
no data available on detecting 
precursors to CRC 
 
no data available on detecting 
CRC in screening-population 
 
test for detection of precursor 
lesions (large adenomas etc.) 
under development 
     small producer affiliated study deals with biomarker for detection of 
invasive colorectal adenocarcinoma only, not detection of precursor le-
sions129 
o study undertaken in non-screening population130 
o study with screening-population underway131 
 development of test for precursor lesions under way, that would shed 
light on possible future benefit as CRC-screening test132 
 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
                                                                                                                                                                                                                                                                                                                 
128 Shastri (2008) p. 1502 
129 deVos (2009) 
130 deVos (2009) 
131 deVos (2009) p. 1345  
132 compare http://www.innovations-report.de/html/berichte/biowissenschaften_chemie/darmkrebs_erkennen_bevor_entsteht_133139.html 
accessed March 14th 2010 
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Table 4.7-4: Detailed characteristics of colonoscopy as CRC-screening test 
Test Evidence 
on 
effectiveness 
Expected par-
ticipation rate 
Number of re-
sulting 
colono-scopies 
Sensitivity of 
test 
Specificity of 
test 
Information 
4. 
Colonoscopy 
C 
limited data available 
on the effect of C-
screening on CRC-
incidence and mortal-
ity 
 
no evidence yet avail-
able from RCTs: re-
sults from two133 
RCTsl expected in 
about 10+  years 
 
NNScope* CRC or ad-
vanced adenomas: 
13 
 
NNScope* CRC: 
125 
unknown 
 
initial data 
20-40% 
 
NL-CoCoS-trial 
anticipates 20-
25% 
250/1,000 
(assuming 
participation 
rate of 25%) 
C is (imperfect) 
reference stan-
dard 
 
insufficient evi-
dence to provide 
precise esti-
mates in com-
munity set-
tings134 
 
CRC: 
>97% 
 
adenomas 
>10mm: 
90-98% 
 
adenomas 
6-9mm: 
87% 
 
miss rates for 
adenomas 
>10mm possibly 
higher than CT-
C135 
  risk of serious complications including death 
 serious harms from community C are about 10 times more common than 
with FS136 
 screening-yield is heavily dependent on the endoscopist 
 participation in C-screening significantly lower than in iFOBT-screening 
 detection rate lower with difference increasing in subsequent 
screening-rounds 
 unpleasant screening-method due to its invasive nature 
 extensive bowel preparation necessary at home on preceding day: drink-
ing of 2 liters of laxative solution 
 participants in screening have to reserve 2 days for entire procedure 
(bowel preparation, aftercare) 
 C itself takes approx. 20 minutes 
 most sensitive existing test for detecting advanced neoplasia (imperfect 
reference standard) 
 C misses some polyps and may also miss CRC137 
 tumors in the right (proximal) colon are harder to detect for C those in 
the left (distal) colon 
o anatomic “blind spots” 
o incomplete bowel preparation 
o incomplete C 
 if needed, polypectomy or biopsy possible during same screening-
procedure 
 evidence for timing of C-screening is limited, suggesting re-screening 
would be needed once every 10 years, or up to 20 years and more138 
 considerable C-capacity required 
COMPLICATIONS of screening-colonoscopy 
 procedure related hospital visits 950/ 100.000139 
 serious complications from C in asymptomatic populations 310/ 
                                                             
133 Barcelona, Spain: Colorectal Cancer Screening in Average-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy 
Trial registered at www.ClinicalTrials.gov with registration no: NCT00906997 
 
once only colonoscopy, NordICC is a multicentre, randomised trial in Nordic countries, the Netherlands and Poland 
Trial is registered at www.ClinicalTrials.gov with registration no: NCT0088379 
134 USPSTF Whitlock (2008) 
135 USPSTF Whitlock (2008a) 
136 USPSTF Whitlock (2008) 
137 USPSTF Whitlock (2008) 
138 e.g. Brenner (2008), Brenner (2010) 
139 Leffler (2010) 
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100,000140 
o perforation: 56/ 100,000141 and 66/ 100,000142 and 50 - 
10/ 100,000143 
o bleeding: 120/ 100,000144 and 60 - 20/100,000145 
 death: most screening-studies indicate no fatal outcomes of screening-C 
o death from colonoscopy for symptomatic patients: 4/ 
100,000 
 patients older than screening-population 
 more co-morbidities 
 more intestinal problems 
o overall death from colonoscopy: 6/ 100,000146 
 from bowel preparation147 
 from sedation, not systematically documented and linked to interven-
tion148 
COMPLICATIONS of follow-up C after positive first-line screening-test are 
higher than for screening-C 
 perforation: 100/ 100,000 
 bleeding: 140/100,000 
* ... On the basis of prevalence figures from the Netherlands: for every 13 people who undergo colonoscopy in the context of screening, just one will be found to have CRC or advanced adenomas. In the 
case of CRC  alone, the figure  is 125 – see Health Council of the Netherlands (2009) 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
 
                                                                                                                                                                                                                                                                                                                 
140 USPSTF Whitlock (2008a) – Serious complications were defined as adverse events requiring hospital admission, including perforation, major bleeding, diverticulitis, severe abdominal pain, cardiovascular events, and deaths attributable to 
colonoscopy (p. 24). 
141 USPSTF Whitlock (2008a) 
142 Van Heijningen (2010) 
143 Health Council of the Netherlands (2009) 
144 USPSTF Whitlock (2008a) 
145 Health Council of the Netherlands (2009) 
146 Van Heijningen (2010) 
147 e.g. Heher (2008) 
148 Lieberman (2009) 
Results part I: Important facts about colorectal cancer-screening 
LBI-HTA | 2010 39 
Table 4.7-5: Detailed characteristics of flexible sigmoidoscopy as CRC-screening test 
Test Evidence 
on 
effectiveness 
Expected par-
ticipation rate
Number of result-
ing colono-
scopies 
Sensitivity of 
test 
Specificity 
of test 
Information 
5. 
Flexible sig-
moidoscopy 
FS 
Results from large multicentre RCT in 
UK149, intention to treat analysis150: 
CRC incidence minus 23% 
CRC mortality minus 31% 
 
Number needed to screen to prevent 
 one CRC diagnosis: 191 
 one CRC death: 489 
 
first results from NOR showed no 
stat. sign. reduction in CRC-
mortality151 
 
with publication of results from RCT 
in USA152 [in the near future153] and 
RCT in ITA154 [later] 
community performance of FS-
screening will become even clearer155 
 
from NL trial: 
 
NNScope* CRC 
 625 invitations 
 207 FS 
 18 C 
 
NNScope* advanced adenomas 
 48 invitations 
 16 FS 
 1-2 C 
10-40% 
 
about 35% 
RCT UK156 
 
32% 
in Rotterdam 
trial 
18/1,000157 
on top of 350 FS 
assuming 35% 
participation rate 
under population 
based screening 
conditions 
 
 
27/1,000 
 
on top of 327 FSs  
 
assuming partici-
pation rate of 
32% 
little data avail-
able concerning 
sensitivity in 
population-
screening 
 
based on C-
studies in aver-
age risk popula-
tion (over-
estimation): 
 
CRC: 
58-75% 
 
advanced neo-
plasia: 
72-86% 
 
  serious harms from community FS are about 10 times less common than with 
C158 
 estimates for harms from FS have much wider confidence intervals159 
 screening-yield is heavily dependent on the endoscopist 
 adequately trained nurse practitioners can undertake FS as competently as can 
gastroenterologists and public acceptance of nurse led flexible sigmoidoscopy 
is high160 
 FS takes only about five minutes, a lot less than colonoscopy 
 uptake significantly lower than for iFOBT-screening (NL trial) 
 uptake would need to be significantly higher than projected 30% (NL trial) to 
render FS an effective screening-method 
 roughly equally sensitive for CRC as single iFOBT 
 significantly more sensitive for advanced adenomas 
 not clear whether screening needs to be repeated every 5 or 10 years 
 procedure takes approx. 7 minutes 
 limited bowel preparation – less extensive than for C 
o enema 120-150ml, possibly self-administered 
o 9-20% of participants have to make new appointment due to 
inadequate preparation 
 no data available concerning an optimum referral threshold to C  test char-
acteristics of screening dependent on it: the lower the threshold 
 the higher the sensitivity 
 the higher the number of participants who have to be referred 
 the higher the number of false positives (i.e. the lower the specificity) 
 no data currently available regarding the effectiveness of FS-screening as a 
means of reducing CRC-mortality 
COMPLICATIONS 
 FS serious complications: 34/100,000 (CI 6-190)161 
o FS perforation: 4.6/ 100,000162 and 2-3/100,000163 
 FS from limited bowel preparation 
 follow up-colonoscopy, see table 4.7-5 
                                                             
149 55- 64 yrs old, once only sigmoidoscopy, median follow up 11.2 years, Atkin (2010) 
150 Intention-to-treat analysis: all participants allotted to the screening group, including those who decided not undergo screening as opposed to per-protocol analysis, only participants actually screened 
151 once only sigmoidoscopy, NORCCAP trial, preliminary results after only 7 years of follow up: Hoff (2009) – NORCCAP is the only study of flexible sigmoidoscopy screening that is truly population based and will provide an estimate for ef-
fectiveness after 10 years of follow-up in 2013. 
152 sigmoidoscopy every 3-5 years, PLCO trial: Weissfeld (2005) 
153 personal e-mail correspondence with Prof. Weissfeld, Nov. 2010 
154 once only sigmoidoscopy, SCORE trial: Segnan (2002) 
155 USPSTF Whitlock (2008) 
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* ... On the basis of prevalence figures from the Netherlands: for  one person to be found to have CRC or advanced adenomas 16 will need to undergo flexible sigmoidoscopy and 1-2 follow-up colonoscopy, 
In the case of CRC  alone, the figures are 207 and 18 – Health Council of the Netherlands (2009) 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
 
                                                                                                                                                                                                                                                                                                                 
156 This figure is an estimate of the participation in a population based screening based on Atkin (2010). This UK RCT was designed to have high power to examine the efficacy of FS (incidence and mortality of CRC). It was not designed to de-
termine realistic participation rates in FS based population based screening. The RCT therefore had a pre-selected population. Participants in RCT were only enrolled after answering “Yes” to the question if they would participate in FS 
screening if invited. This meant that the compliance rate in the trial was (much) higher than would be expected in population based screening. Of the invited 71% participated in FS screening. But 47% of the potential screening population 
were excluded from being invited. Assuming that the excluded would not have participated in the screening the participation rate in a population based screening might be estimated to be a little above 35%. 
157 High referral threshold to colonoscopy in UK RCT, only 5% referred to colonoscopy with 4% entering surveillance program Atkin (2010), referral thresholds lower in NORCCAP and PLCO trials, resulting in 3 to 4 times higher rates of fol-
low up colonoscopies (with  the added consequences on the rate of referral to surveillance regimes. 
158 USPSTF Whitlock (2008) 
159 USPSTF Whitlock (2008) 
160 Atkin (2010) 
161 USPSTF Whitlock (2008a) – Serious complications were defined – in analogy to colonoscopy – as adverse events requiring hospital admission, including perforation, major bleeding, diverticulitis, severe abdominal complaints, myocardial 
infarction, syncope, and deaths attributable to flexible sigmoidoscopy (p. 26). 
162 USPSTF Whitlock (2008a) 
163 Health Council of the Netherlands (2009) 
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Table 4.7-6: Detailed characteristics of capsule endoscopy as CRC-screening test and new developments in endoscopy 
Test Evidence 
on 
effectiveness 
 
Expected par-
ticipation rate 
Number of re-
sulting co-
lono-scopies 
 
Sensitivity of 
test 
Specificity of 
test 
Information 
6. 
Capsule endo-
scopy 
CE 
small, producer spon-
sored studies only 
no data avail-
able 
 CRC 
74%164 
76%165 
adenomas 
>6mm 
64%166 
68%167 
adenomas 
>10mm: 
64 % 
Adenomas 
>6mm 
82%168 
 CE has been widely used to analyze pathologies of the small intestine 
for several years169 
 current price of a capsule approx. € 950.-170 
 need for extensive bowel preparation, more extensive than for colono-
scopy or CT-colonography 
 within the upcoming 7 years, improvements are expected to make CE 
suitable for use as a method of CRC-screening 
 randomized studies, involving comparisons with existing screening-
methods, will then have to be carried out to determine whether CE can 
actually improve the efficacy or efficiency of screening 
 battery life limits the use of this technique as a screening-method for 
CRC 
o remedy: use of capsules with delayed activation, reduced 
energy consumption, increased battery capacity 
COMPLICATIONS 
 CE: from bowel preparation 
 follow up-colonoscopy, see table 4.7-5 
New develop-
ments in endo-
scopy 
      more adenomas can be detected using chromoscopy (colonoscopy in 
which the intestinal wall is stained) 
 this technique is very time consuming and does not appear to be suitable 
for use as a general screening-method 
 same is true of 
o high-definition endoscopes 
o auto fluorescence narrow-band imaging 
Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
                                                             
164 producer supported study on 320 patients, Van Gossum (2009), sensitivity probably overestimated compare Bretthauer (2009) 
165 Meta analysis of 8 studies with data on 837 patients, Spada (2010) 
166 Van Gossum (2009) 
167 Spada (2010) 
168 Spada (2010) 
169 Capsule endoscopy has become part of the reimbursement basket for Germany’s social health insurance to investigate unclear bleeding in the small intestine in November 2010. See Gemeinsamer Bundesausschuss, www.g-ba.de 
170 Bretthauer (2009) 
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Table 4.7-7: Detailed characteristics of CT-colonography as CRC-screening test 
Test Evidence 
on 
effectiveness 
 
Expected partici-
pation rate 
Number of re-
sulting colono-
scopies 
 
Sensitivity of test Specificity of test Information 
7. 
Computed-
Tomography 
colonography 
CT-C 
no evidence from ran-
domized trials that CT-C 
reduces CRC-incidence 
and CRC-mortality 
Unknown 20/1,000 
 
assuming a par-
ticipation rate 
of 35% and a 
polyp referral 
threshold of 
10mm 
 
referral thresh-
old of 6mm 
approx. doubles 
number of Cs 
limited evidence 
on performance 
in population 
screening-
programs 
 
variability be-
tween readers 
limits ability to 
provide precise 
estimates171 
 
advanced neopla-
sia: 
97% 
 
less sensitive for 
small adenomas 
 
detection of ade-
nomas >10mm 
possibly higher 
than C172 
limited evidence 
on performance 
in population 
screening-
programs 
 
estimates are 
somewhat uncer-
tain173 
 
for large polyps: 
>95% 
 
PPV advanced 
adenomas: 
 
41% 
(referral thresh-
old 6mm) 
 
52-67% 
(referral thresh-
old 10mm) 
 almost identical sensitivity for CRC-cancer and polyps >10mm as C 
o possibly more sensitive for larger lesions than C, less so for 
smaller lesions174 
 screening-yield is heavily dependent on radiologist 
 variety of technologies used175 
o varying slice thickness 
o single/multi detector scanner 
o 2D/ 3D/ 3D fly-through 
o oral contrast 
 radiation dosage expected to decline with future progress in CT-
technology: 
o lower radiation exposer for CRC-screenees  
o low radiation dosage reduces image quality outside the co-
lon and is expected to significantly reduce the number of 
referrals176 
 less unpleasant for subject than C 
 clear preference for CT-C in studies of subjects’ experience 
 clear preference for CT-C in people who have undergone both CT-C and C 
 may be superior to C for detecting proximal CRC 
 sessile (flat) abnormalities – as opposed to much more common peduncu-
lated (spherical) polyps – are difficult to detect 
 less likely to have serious complications than C 
 limited bowel preparation – less than for C 
 no agreement on best referral threshold to C – usually ≥ 6 mm  test 
characteristics of screening dependent on it: the lower the threshold 
 the higher the sensitivity 
 the higher the number of participants who have to be referred to C 
 the higher the number of false positives (i.e. the lower the specific-
ity) 
 examination takes about 15 mins., reading about 10 mins. 
 
COMPLICATIONS 
 CT-C radiation 
 CT-C issue of extra-colonic findings unresolved 
 CT-C from limited bowel preparation 
 CT-C as yet no perforation reported in limited use as a screening-method 
 follow up-colonoscopy, see table 4.7-5 
                                                             
171 USPSTF Whitlock (2008) 
172 USPSTF Whitlock (2008a) 
173 USPSTF Whitlock (2008) 
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Abbreviations: see table 4.7-1 above   
Source:  information from Health Council of the Netherlands (2009), adopted with specifically cited inputs 
 
 
                                                                                                                                                                                                                                                                                                                 
174 USPSTF Whitlock (2008) 
175 USPSTF Whitlock (2008a) 
176Health Council of the Netherlands (2009), p. 68 
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4.8 CRC-screening activities worldwide 
European Union 
Finland, England and Scotland are currently working on the phased intro-
duction of nationwide population-based screening-programs.177 Nationwide 
population-based programs are at the preparatory stage in 5 other countries, 
while France, Spain, Italy and Sweden already have population screening-
programs in place at regional level. Italy has a national body for the evalua-
tion of its 72 regional screening-programs for CRC. In total, the population-
based programs that are either in preparation or already under way cover 43 
% of the target population in the EU178. Many countries have a variety of 
obstacles to a nationwide population-based program, such as a decentralized 
health care services and public-health policy determination. For example, 
Germany, Austria and the Czech Republic have established non-population-
based programs. Screening in those countries is carried out on an individual 
basis (27% of the target group). This is referred to as opportunistic screen-
ing. The participation rates involved are low. 8 of the 27 member states have 
yet to start preparing screening-programs of their own. In 2007, 12 million 
people actually underwent screening for CRC. On the basis of a biennial 
screening, this represents 18% of the target group. In almost every case, 
member states opted for gFOBT-screening. Italy selected iFOBT-screening 
and the UK is considering a switch to that system in the near future. The 
primary screening-test in Poland is colonoscopy. In 6 countries, endoscopic 
screening is used in combination with – or as an alternative to – FOBT-
screening. 5 of these states (including Germany) use colonoscopy while Italy 
uses flexible sigmoidoscopy. 
 
In Ireland a national colorectal cancer screening programme for men and 
women aged 55 to 74 is scheduled for introduction in January 2012. The 
program will be based on IFOBT as first line test every two years. Procure-
ment of IFOBT kits will be completed by mid 2011. Screening colonoscopies 
after referrals will take place at contracted units in hospitals.179 In advance 
of the decision to organise a population based screening program the Irish 
government commissioned a thorough analysis of screening options and im-
portant issues to be considered. These HTA documents can be downloaded 
on the internet.180 
 
EU guidelines for colorectal cancer screening in preparation 
 
Comprehensive guidelines for quality assurance of colorectal cancer screen-
ing which are suitable for implementation throughout the 27 EU Member 
States are currently being developed in a project which is coordinated by In-
ternational Agency for Research on Cancer IARC and co-funded by the EU 
Health Programme. The most fundamental principle being that screening 
should be implemented in the context of an organized, population-based 
programme following comprehensive quality assurance guidelines. Adequate 
                                                             
177 For this section compare Health Council of the Netherlands (2009) p. 21 
178 For the situation in the EU compare also e.g. Gutierrez-Ibarluzea (2008) 
179 www.cancerscreening.ie und 
www.cancerscreening.ie/publications/ImplementingColorectalProgramme.pdf 
180 www.hiqa.ie/news_releases/090617_HTA_colorectal_cancer_screening_programme.asp 
Finland, England, 
Scotland phase in 
population-based 
screening 
43% of target 
population in EU have 
access to some sort of 
screening 
opportunistic screening 
with low participation 
rate 
gFOBT most common 
test 
 
 
 
 
 
 
 
Ireland to indtroduce 
iFOBT population based 
screening program from 
2012 
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attention needs to be paid to planning and training, identification and in-
formation of the target population, multidisciplinary management of de-
tected lesions, as well as to coordination, monitoring and evaluation.181 
 
Outside the EU 
Countries like Australia and 3 of the 10 Canadian provinces have com-
menced the phased introduction of population-screening based on gFOBT, 
iFOBT or flexible sigmoidoscopy. In the US, Japan and Taiwan, screening 
takes place on an individual basis. Colonoscopy is the most widely used 
technique in the US. In 2002, 14 million colonoscopies were carried out in 
the US, approximately 40% of which involved primary screening. Colono-
scopy utilization for screening has increased recently, and use of flexible sig-
moidoscopy decreased, due largely to the decision in 2001 to cover screen-
ing-colonoscopy for patients on Medicare, and similar decisions by private 
pay insurers.182 Over 20% of colonoscopies in the US were performed as part 
of the surveillance of high-risk groups. Japanese citizens who are over 40 
years of age and who have health insurance cover have been offered iFOBT-
screening since 1992. Only 17% of the target group made use of this facility 
in 2002. There is no provision for the evaluation of the screening-program. 
The sum total of current programs throughout the world represents a con-
siderable amount of screening-activity. Many such programs have been un-
der way for many years, as in Japan, Italy and Germany. Nevertheless, only a 
few countries have well organized, nationwide, population-based screening-
programs. 
4.9 Current CRC-screening recommendations 
by selected institutions 
When analyzing CRC-screening recommendations, the different respective 
health system background, stakeholder pressures and target audience for the 
screening-recommendations should be born in mind. The Health Council of 
the Netherlands for instance, got the specific task from the minister of 
health to formulate recommendations for a national screening-program that 
should take the results of local pilot programs into account.183 The United 
States Preventive Services Task Force addresses the heterogeneous US-
healthcare system where only the Veterans Administration runs a CRC-
screening program. 
“Although the term evidence-based may suggest that guidelines simply 
emerge from evidence, guidelines making is a human process, like creating 
and operating a judicial system is a human process, requiring structure and 
process to make it function properly. In other words, it is inherently a politi-
cal process and should be managed as such.”184 
                                                             
181 Lecture Lawrence von Karsa, IARC 
www.transatlantic-symposium.de/abstracts/lawrence-von-karsa/index.php 
182 USPSTF Whitlock (2008a) p. 7 
183 Health Council of the Netherlands (2009) 
184 Imperiale (2010) 
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screening 
Colonoscopy main 
screening-test in US 
only little well 
organized, nationwide, 
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different perspectives 
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science-base for CRC-
screening rapidly 
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Screening for CRC has a rapidly evolving science base, such that guidance 
may be expected to change as additional research becomes available.185 This 
may for instance be happening in regards to flexible sigmoidoscopy screen-
ing after the recent publications of a large randomised controlled trial in the 
UK186: 
“Colorectal cancer screening guidelines usually recommend flexible sigmoi-
doscopy with a five year screening interval. In light of the UK trial, longer 
screening intervals should be recommended.”187 
Table 4.9-1: Selected CRC-screening recommendations 
Institution 
 
Date Recommendation Comment 
Health Council of the 
Netherlands 
NL 
2009  55-75 years 
 iFOBT 75 ng/ml 
 every 2 years 
  
USPSTF 
US 
2008  50-75 years 
 
 FOBT or 
 flexible sigmoido-
scopy or 
 colonoscopy 
 first USPSTF recommendation for CRC-
screening in 1996 
 current recommendations based on update 
of 2002 systematic review 
 previous USPSTF recommendations from 
2002 do not give suggest upper limit of 
screening-age 
OHTAC 
CAN 
2009  from 50 years 
 FOBT 
 every 2 years 
  
EPAGE II 
international 
2008  from 50 years 
 colonoscopy 
  
 
Abbrevia-
tions: 
CAN … Canada 
 EPAGE II… European Panel on the Appropriateness of Gastrointestinal Endoscopy, www.epage.ch 
 FOBT … faecal occult blood test 
 iFOBT … immunochemical faecal occult blood test 
 OHTAC … Ontario Health Technology Advisory Committee 
 ng/ml … nanogram per millilitre  
 NL … Netherlands 
 US … United States of America 
 USPSTF … United States Preventive Services Task Force 
Source: Health Council of the Netherlands (2009), USPSTF (2008), OHTAC (2009), EPAGE II see Arditi 
(2008) 
                                                             
185 USPSTF Whitlock (2008a) 
186 Atkin (2010) 
187 Betthauer (2010) p. 1260 
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4.10 Detailed CRC-screening program 
recommendations, the example of the 
Netherlands 
Criteria 
 simplicity 
 acceptance 
 performance/ test characteristics 
 safety 
 
Recommendation for CRC-screening in NL 
 immunochemical Faecal Occult Blood Test (iFOBT), a self test 
 product: OC-sensor 
 single faecal sample 
 threshold 75 ng/ml (provisional recommendation due to lack of co-
lonoscopy capacity in NL today) 
 every 2 years 
 followed by colonoscopy in case of positive test result in outpatient 
clinic under sedation and with the aid of pain management 
 targeted group: women and men aged 55-75 
 (referral to screening thereafter to be decided individually with 
GP) 
 
Anticipated results from modelling 
 Number needed to treat (life saved from CRC) 
 785 people would need to complete iFOBTs 
 40 follow-up colonoscopies 
 EUR 2,200.- per life year gained (assuming participation rate of 60% 
derived from iFOBT-pilot trials conducted in the run up to the deci-
sion of introducing a national CRC-screening program in NL) 
 
 
Netherlands have 
program focus 
iFOBT75 
every 2 years 
 
age 55-75 
 
 
 
NNT: 785 iFOBTs, 40 
colonoscopies 
 
EUR 2,200.- per life year 
gained 
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Table 4.10-1: Health Council of the Netherlands: relative merit of six screening-methods 
 gFOBT 
 
iFOBT75 Molecular  
markers 
Colonoscopy Flexible  
Sigmoido-scopy 
CT –  
colonography 
Attendance 
 
+ ++ ? ? - ? 
Evidence 
 
++ + +/- +/- +/- +/- 
Test performance 
 
+/- ++ + ++ ++/- ++ 
Less burdensome 
 
+ ++ +   +/- 
Less risk 
 
++ ++ ++  + + 
Cost-effective 
 
+ ++ ? +? +? ? 
Less colonoscopy capacity needs 
 
++ + ?    
 
Abbreviations: CT … computed tomography 
 gFOBT … guaiac faecal occult blood test 
 iFOBT75 … immunochemical faecal occult blood test – threshold 75 nanograms per millilitre 
 
Source: 
 
adapted from table 5, Health Council of the Netherlands (2009) p. 80 
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5 Results part II: Important questions to ask about 
CRC-screening and program design 
5.1 Why is screening different? 
Screening for disease is not a logical extension of ordinary medical practice. 
The ethical position is quite different. Screening involves an unsolicited of-
fer to in principle healthy persons. These exceptional characteristics mean 
that screening is justified only if it is demonstrably advantageous. Proof of 
principle alone – i.e. reduction of all-cause or disease-specific mortality 
through CRC-screening – is not enough for the introduction of screening: 
balancing of downsides with benefits is necessary.188 
Early detection must have a positive net health benefit. Only a minority of 
people undergoing screening stands to benefit directly from participation. In 
the case of CRC-screening, although CRC is a common cancer, the lifetime 
risk for an individual is actually quite low, 5%189 The lifetime mortality rate 
in the US is 2.4% for women and 3.3% for men.190 So more than 95% of 
people have no benefit from CRC-screening but are still exposed to the po-
tential harms of it. Even if CRC-screening was to completely eliminate 
CRC-cancer (which it does not), it is still necessary to carefully weigh up the 
pros and cons of any such program.191 It is by no means implausible that the 
desirable effects of a given form of screening will be outweighed by the un-
desirable effects: false positive results, false negative results, over-diagnosis, 
overtreatment etc.. As a consequence it is very important that the design of a 
screening-program meets high quality standards, maximizes desirable ef-
fects and minimizes undesirable effects. Because a screening-program is 
made up of numerous diverse constituent activities, professional organiza-
tion and effective management are vital.192 
Given potential harms and observed variability in test accuracy, emphasis on 
quality standards für implementation of any operator-dependent CRC-
screening test appears prudent.193 
                                                             
188 e.g. Health Council of the Netherlands (2009), Raffle (2009), Saul H. Interview with Michael Baum: 
Shooting sacred cows. Cancer Futures 2003;2;273-8 
189 e.g. Baxter (2010); US CRC-lifetime risk males 5.9% (lifetime mortality rate 2.4%), females 5.4% 
(lifetime mortality rate 3.3%) - USPSTF Whitlock (2008a) 
190 USPSTF Whitlock (2008a) 
191 Health Council of the Netherlands (2009) p. 33 
192 Health Council of the Netherlands (2009) p. 107 
193 USPSTF Whitlock (2008) 
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5.2 What is NOT known about CRC-
screening? 
At this point in time reliable evidence is lacking in some areas giving rise to 
uncertainties and open questions about CRC-screening. These issues still 
need to be dealt with when establishing an organized program: 
5.2.1 Effectiveness of CRC-screening 
 ??? no high-grade evidence (randomized controlled trials) for impact 
of any form of CRC-screening on all-cause mortality 
 ??? no high-grade evidence for reduction of disease-specific mortality 
other than for CRC-screening with gFOBT and once only flexible 
sigmoidoscopy 
 none for colonoscopy (expected in 10+ years), CT-
colonography, capsule endoscopy, molecular test 
 ??? evidence from screening-setting in clinical practice very limited194, 
including on complications195- there is evidence that complications 
might have been underestimated196 
 Norway’s NORCCAP is the only study (on flexible sigmoidoscopy) 
that is truly population based and will provide an estimate after 10 
years of follow up in 2013197 
 
5.2.2 Parameters relevant for CRC-screening 
 ??? optimal referral threshold (number of polyps, size of polyps) 
 ? iFOBT to colonoscopy 
 ? flexible sigmoidoscopy to colonoscopy 
 appropriate polyp size threshold for referral to 
colonoscopy is not well-established, thus colono-
scopy referral often follows detection of any lesion 
on flexible sigmoidoscopy198 
 ? CT- colonography to colonoscopy 
 ??? optimal screening-interval 
 ? iFOBT – 1 year?, 2 years?, more? 
 ? flexible sigmoidoscopy – 5 years?, more?199 
 ? colonoscopy200 – 10 years?, up to 20 years?, more? 
 recent evidence from epidemiological studies 
suggests that intervals for screening with colono-
scopy might be extended to 20 years or even 
                                                             
194 e.g. Lieberman (2009), Brenner (2010) 
195 e.g. Lieberman (2009), Betthauer (2010) 
196 E.g. Leffler (2010) 
197 Hoff (2009) 
198 USPSTF Whitlock (2008a) 
199 Bretthauer (2010) 
200 e.g. Brenner (2010) 
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be addressed in program 
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effectiveness of CRC-
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longer, as subjects with negative findings at endo-
scopy are at very low risk for at least 20 more 
years201 
 
 
 
 ??? iFOBT 
 ? optimal test of the many available iFOBTs202 
 ? optimal number of stool samples to take203 
 
 ??? colonoscopy 
 there is evidence of much lower yields of proximal/ right-
sided vs. distal/ left-sided CRC 
 ? causality of this difference not fully under-
stood204 
 ? repercussions for decision between colono-
scopy and flexible sigmoidoscopy unad-
dressed205 
 ? hygiene standards and adverse events (e.g. double wash-
ing of endoscopic equipment and infectious disease trans-
mission) 
 ??? screening-program level 
 general 
 ? influence divergent rates of adenoma detection 
might have on screening-goal of prevention of 
CRC unclear206 
 does focus on detection rate (including 
small adenomas) make sense? 
 there is relatively small clinical benefit 
of detecting and removing very small 
polyps207 
 recommendation for screen-detected larger ade-
nomas >10mm is clear: removal; but optimal 
screening-regime for dealing with smaller ade-
nomas unclear 
 ? 6-10mm 
 ? < 6mm? 
 ? optimal surveillance regime 
 screening may induce lifestyle changes that might 
negatively affect benefit, e.g. 
o ? impact of negative polyp test 
on tobacco use208 
o ? impact of negative polyp test 
on dietary habits (obesity)209 
                                                             
201 e.g. Brenner (2008) 
202 e.g. Lieberman (2009) 
203 e.g. Hundt (2009), Lieberman (2009) 
204 e.g. Baxter (2009), Brenner (2010) 
205 e.g. Baxter (2010) 
206 e.g. Baxter (2010) 
207 e.g. Barclay (2006) 
208 e.g. Levin (2002) 
209 e.g. Levin (2002) 
causality of 
colonoscopy’s lower 
yield of proximal/ right-
sided CRC unclear 
influence of adenoma 
detection on CRC 
unclear 
 
 
 
optimal screening-
guideline for detected 
adenomas < 10mm 
unclear 
 
optimal surveillance 
regime unclear 
 
influence of screening 
on lifestyle changes 
unclear 
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 test-specific program organization issues 
 ? iFOBT: management of interval between faecal 
sampling at individual’s home and analysis at lab 
 faecal samples used for iFOBT prone to 
denaturation: their quality is very impor-
tant 
 dating of samples by participants does 
not work well 
 storage/ temperature exposure of sample 
before arrival at analysis not easily con-
trollable 
o e.g. Australia (and potentially 
Canada) send out iFOBTs only 
in cooler months of the year210 
 ? colonoscopy 
 formulation of program-aim aligned 
financial incentives for examiners211 
o remuneration per screening-
colonoscopy? 
 caveat: incentive to per-
form screening-
colonoscopy rapidly 
o remuneration linked to yield 
(adenoma detected and re-
moved)? 
 caveat: if this really con-
tributes to aim of 
screening-program is 
unknown 
o setting of colonoscopy remu-
neration relative to remunera-
tion for flexible sigmoidoscopy? 
 formulation of quality indicators for 
monitoring that are meaningful in 
terms of achieving program aim 
(withdrawal time?, …)212 
 
 
                                                             
210 Health Council of the Netherlands (2009) p. 114 
211 e.g. Barclay (2006), Gupta (2007), Lieberman (2009) 
212 e.g. Barclay (2006) 
best management of 
iFOBT home-testing 
unclear 
optimal financial 
incentives for screening-
colonoscopy unclear 
optimal quality 
indicators for screening-
colonoscopy unknown 
program quality and 
participation rate more 
important than choice 
of first-line screening-
test 
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5.3 Essentials to keep in mind when 
designing a population based CRC-
screening program 
5.3.1 Program design 
Installation of screening-program structure with view to 
 assuring quality 
 sustainability 
 
Informed consent of screening-participants 
 significance attached to ensuring that participation deci-
sions can be made freely increases213 
 non-participation must not entail negative conse-
quences for individuals, neither in relationship 
with their health insurance provider, nor with 
their physician214 
 ensuring that participation can be based on informed 
choice is vital for screening-program’s legitimacy 
o e.g.: FOBT testing 
 test itself entirely safe 
 positive test result implies referral for 
colonoscopy 
 potential participants must therefore be 
made aware of the albeit small risk of se-
rious complications associated with 
colonoscopy before they decide whether 
to have the initial “harmless” FOBT 
test215 
 informed choice is not easy to achieve 
o screening is a complex process not generally well 
understood by professionals and the public for a 
range of reasons216 
o decision-making about screening involves com-
plex risk assessment 
o many people overestimate the benefit of screening 
o screening-providers are inclined to stress benefits 
and trivialize drawbacks217 
 information to be given by program and provider inde-
pendent institution 
why? 
o (high) participation rate determines success of 
screening-program  program organizers biased 
o participation rate determines provider income  
operator/ examiner/ reader biased 
 
 
                                                             
213 Health Council of the Netherlands (2009) p. 99 
214 OHTAC (2009) p. 4 
215 Health Council of the Netherlands (2009) p. 101 
216 National Health Committee (2003) p. 2 
217 Health Council of the Netherlands (2009) p. 101 
informed consent to 
screening 
 
no negative 
consequences for non-
participants 
information from 
program and provider 
independent institution 
 
e.g. Nordic Cochrane 
Centre 
Screening for Colorectal Cancer 
54 LBI-HTA | 2010 
by who? 
o e.g. Nordic Cochrane Centre, Copenhagen, Den-
mark218 
o e.g. University of Hamburg, Fachwissenschaft Ge-
sundheit, Germany219 
 
5.3.2 Offering potential participants a choice of 
first-line screening-test 
 Is choice valued in itself? 
o YES: attitude survey conducted among colono-
scopy-naive individuals showed that, once they 
had been fully informed about the techniques in 
question, most people preferred FOBT-screening 
to colonoscopy220 
o possible options for choice in CRC-screening 
 FOBT or colonoscopy 
 FOBT or flexible sigmoidoscopy 
o if the results of flexible sigmoidoscopy-screening 
trials in England and Italy (expected later in 
2010) confirm the expected mortality reductions, 
consideration could be given to investigating the 
feasibility of combining flexible sigmoidoscopy-
screening with FOBT-screening and offering the 
choice between the two methods221 
 Is choice a tool to increase participation? 
o NO: currently no data available to support that 
implementing a multi-option program would re-
sult in higher participation or increase the effec-
tiveness of screening222 
 
                                                             
218 download for breast cancer screening in English: www.cochrane.dk/screening/index-en.htm or in 
German: http://www.cochrane.dk/screening/index-de.htm , accessed March 14th, 2010 
219 download for CRC-screening in German: http://www.gesundheit.uni-hamburg.de/cgi-
bin/newsite/index.php?page=page_46 , accessed March 14th, 2010 
220 Health Council of the Netherlands (2009) p. 62 
221 Health Council of the Netherlands (2009) p. 81 
222 Health Council of the Netherlands (2009) p. 93 
choice of first-line 
screening test valued 
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5.3.3 Selection of screening-test(s) to use in 
population based program 
 expected influence of a test/ choice of tests on participa-
tion rate central for program’s decision 
“’The best test is the one that the patient will accept’ was 
often stated by experts”223 
 program test characteristics (incorporating participation 
rate) matter from a public health point of view – single 
test characteristics are of only theoretical interest 
 evidence of test characteristics in real-world setting/ 
screening-context relevant, not evidence from artificial 
trial setting/ symptomatic-test setting 
 the greater the sensitivity of a test (e.g. colonoscopy) for 
gradually developing abnormalities (e.g. CRC), the less 
advantage there is in having a shorter test interval224 
 
5.3.4 Program guidelines 
 development of integrated (multidisciplinary) guidelines 
covering the entire chain from screening to diagnosis, 
treatment, follow-up and surveillance as evidence-based 
backbone of population based screening-program 
 
 
5.3.5 Quality 
 if the potential benefit of screening is to be realized, steps 
must be taken to ensure that the quality of colonoscopy 
examinations is of an appropriate standard225  
o all screening-designs, independent of initial test 
(gFOBT, iFOBT, flexible sigmoidoscopy), ultimately 
rely on colonoscopy for effectiveness 
o if an adenoma is detected, the most important issue is 
that the abnormality will be fully removed during 
colonoscopic polypectomy 
 the biggest risk factor for adenoma patients in re-
lation to the development of CRC is incomplete 
adenoma removal226 
                                                             
223 Imperiale (2010) p. 1642 
224 Health Council of the Netherlands (2009) p. 95 
225 Health Council of the Netherlands (2009) p. 118 
226 Health Council of the Netherlands (2009) p. 119 
impact of screening test 
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integrated guidelines 
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quality of colonoscopy is 
key 
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 quality of endoscopists (training, continued education and 
experience) determines screening-yield and rate of adverse 
events 
o roles of different health professions in screening-
program (capabilities, legal requirements, …) – e.g. 
nurse endoscopists 
 provision of necessary quantity of qualified human re-
sources for screening 
 CRC beyond screening: professional staff and facilities for 
diagnosis and treatment need to be sufficiently well devel-
oped to cope with the volume of referrals that a national 
screening-program would generate 
 screening is only desirable once the necessary follow-
up care capacity has been built up 
 Process of Quality Assurance 
 accreditation for endoscopists 
o experience 
o continued education 
o meeting of process parameters, e.g. 
 proof of full colonoscopy (image of 
cecum) 
 withdrawal time 
 adenoma detection rate 
 complication rate 
 installation of reliable system to gather data on unin-
tended consequences of screening activity (i.e. hospi-
tal stays after screening endoscopies)227 
 quality assurance is more difficult but still essential in 
those areas, the screening-program does not have di-
rect management or funding control over 
o depending on local health care system: diag-
nostics, treatment, surveillance … 
 follow procedural and data protocol including stan-
dardized, uniform documentation of detected abnor-
malities (essential for evaluation) 
 pathology diagnoses will be the primary outcome on 
which the program is evaluated228 
 quality assurance in the domain of pathology 
is key 
 special considerations according to chosen screening-
test: e.g. in the case of iFOBT-based screening 
o iFOB-testing is automated and its quality is 
easy to control 
o focus of quality assurance therefore not on 
the screening-test itself but on 
 organization of sample transport 
from participants to lab 
 follow-up testing and examination 
(colonoscopy, histopathology) 
 
                                                             
227 e.g. Leffler (2010) 
228 Health Council of the Netherlands (2009) p. 126 
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Results part II: important questions about CRC-screening and program design 
LBI-HTA | 2010 57 
5.3.6 Surveillance 
 design of surveillance229 thresholds has mayor impact on 
number of colonoscopies resulting from screening  un-
managed program may easily lead to explosion in number 
of surveillance colonoscopies 
 existing CRC-surveillance regimes practiced the world 
over today problematic 
o population-based screening-program calls for re-
formulation: underlying guidelines were intended 
for normal clinical practice rather than for 
screen-detected adenomas 
o current guidelines are stricter than supported by 
scientific evidence 
o (already strict) guidelines interpreted even stricter 
in actual practice  too many patients are under-
going surveillance colonoscopies 
 elements of colonoscopy capacity230 
1. screening 
2. diagnosis, polypectomy (polyp removal) 
3. surveillance (25-40 % today, present level increas-
ingly seen as excessive, danger of further increase 
through unmanaged screening-program) 
o of the above, surveillance colonoscopy has 
 lowest yield 
 worst benefit-harms trade-off 
 
5.3.7 Flexibility 
 culture of flexibility independent of initial program setup 
desirable 
 mission statement: “Our screening-program focuses on the 
maximum benefit for the population.” 
o ongoing critical evaluation by program itself and 
through independent (outside/ foreign) institu-
tion 
o openness to new (scientific or evidence) develop-
ments 
 mission statement not: “Our screening-
program conducts the best possible 
screening with the chosen test X.” as this 
would result in locking-in of initial deci-
sions 
 a new test could be introduced within the existing infra-
structure of the operational program, since various key 
elements of a CRC-program – such as a call/recall system 
and colonoscopy capacity – would be test-independent231 
                                                             
229 Health Council of the Netherlands (2009) p. 120; for examples on surveillance guidelines compare 
for EPAGE II recommendations Arditi (2009) or for American Cancer Society and US Multi-Society 
Task Force on Colorectal Cancer recommendations Brooks (2008) 
230 Health Council of the Netherlands (2009) p. 120 
231 Health Council of the Netherlands (2009) p. 81 
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5.3.8 International and research focus 
 program culture focusing on international best-practice 
o transparency 
o sharing knowledge 
o investing in partnership 
o learning from each other 
o (research) leadership 
 enable program to generate new scientific evidence 
o before introduction of program: setting up of smaller 
pilot projects generating specific national data needed 
for conceptualization of nationwide screening-
program 
 e.g. NL232 
o during roll-out: due to small effect sizes involved in 
screening-studies: randomized trials on screening-
effectiveness need large number of participants and 
long follow-up to establish effectiveness of preventing 
deaths, these trials are expensive  in absence of tri-
als the results of screening may remain inconclusive 
 roll-out of screening-program offers possibil-
ity for experimental design to gather evi-
dence on effectiveness of screening at small 
additional cost 
 every population based public health pro-
gram for CRC-screening using any primary 
test modality should be launched with ran-
domization of the target population at the 
implementation phase233 
o after introduction of program: program evaluation 
and introduction of pilots within the larger screening-
program 
 e.g. design of program should enable trials of 
potentially preferable test methods per-
formed as flanking studies within the context 
of the operational program234 
 
5.3.9 Consideration of phased/staged introduction 
 roll-out of CRC-screening program is complex 
 ‘teething problems’ during initial stage of newly estab-
lished program more easily addressed with phased intro-
duction 
 first stages of introduction can provide necessary data for 
calibrating national program 
 roll-out options Switzerland 
o population centers below the Canton-level 
o individual Cantons 
o all of Switzerland 
                                                             
232 Health Council of the Netherlands (2009) 
233 e.g. Malila (2008) 
234 Health Council of the Netherlands (2009) p. 82 
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5.3.10 Program financing 
 well managed screening needs resources for program over-
head 
o call/recall system 
o training, continued education and program-
accreditation of examiners 
o data/ IT system 
o quality assurance 
o from the outset, budgetary provision should also be 
made for 
 monitoring and evaluation 
 reference system 
 promotion of knowledge and innovation-
oriented scientific research, necessary to keep 
the screening-program up to date 
 monetary provisions for independent information of par-
ticipants 
 budget for regular program evaluation from independent 
(outside/foreign) institution 
 
sustainable and 
comprehensive 
financing of program 
necessary to achieve 
screening-goals 
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6 Conclusion: Take-home message from review of 
literature in a nutshell 
 program design (quality) and participation rate matter 
 choice of screening-test is of secondary importance 
 
 
 
 CRC-screening is not simply about choosing the right initial 
test for screening 
 
 effective CRC-screening is about establishing of quality as-
sured screening-program integrating diagnosis, treatment and 
surveillance 
o emphasis on quality focused human resource devel-
opment of endoscopists 
 
 uptake is the primary determinant of effectiveness for a screen-
ing-program 
 
 level of participation has a greater influence than the sensitiv-
ity of the screening-test235 
 
 particularly in the context of a population-based screening-
program for slowly developing abnormalities (e.g. for CRC), 
regular participation is likely to be more important than high 
test sensitivity236 
 study of determinants of participation rate warranted 
to inform program design237 
 
 quality of screening-program (narrower realm of screening plus 
integration of diagnosis – treatment – surveillance) affects de-
sired outcome of mortality reduction and minimization of 
negative repercussions on screened population 
 
 
                                                             
235 Health Council of the Netherlands (2009) p. 99 
236 Health Council of the Netherlands (2009) p. 95 
237 e.g. Holden (2010) 
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